| Fertility and Sterility | 81.0 | 2 | 3 |
| Prelude Fertility | 71.7 | 3 | 1 |
| Pacific Fertility Center Los Angeles (PFCLA) | 71.7 | 3 | 1 |
| Colorado Center for Reproductive Medicine | 61.0 | 2 | 1 |
| Michigan Reproductive Medicine | 61.0 | 2 | 1 |
| Mayo Clinic | 60.0 | 4 | 0 |
| Cleveland Clinic | 60.0 | 4 | 0 |
| National Institute for Occupational Safety and Health | 51.7 | 3 | 0 |
| National Geographic Traveler | 51.7 | 3 | 0 |
| Vital and health statistics. Series 21, Data on natality, marriage, and divorce | 51.7 | 3 | 0 |
| Vital and health statistics. Series 5, Comparative international vital and health statistics reports | 51.7 | 3 | 0 |
| Pacific Fertility Center | 51.7 | 3 | 0 |
| Office of Readiness and Response | 51.7 | 3 | 0 |
| American Society for Reproductive Medicine | 45.8 | 1 | 1 |
| Reproductive Medicine Associates of New York | 45.8 | 1 | 1 |
| Reproductive Medicine Associates of New Jersey | 45.8 | 1 | 1 |
| Newsweek | 41.0 | 2 | 0 |
| Ferring Pharmaceuticals | 41.0 | 2 | 0 |
| Epi Info | 41.0 | 2 | 0 |
| Weill Cornell Medicine | 41.0 | 2 | 0 |
| Preventing Chronic Disease | 41.0 | 2 | 0 |
| Rock Stars | 41.0 | 2 | 0 |
| National Survey of Family Growth | 41.0 | 2 | 0 |
| National Vital Statistics System | 41.0 | 2 | 0 |
| NIOSH Power Tools Database | 41.0 | 2 | 0 |
| UCLA Health System | 41.0 | 2 | 0 |
| NewYork-Presbyterian Westchester | 41.0 | 2 | 0 |
| Morbidity and Mortality Weekly Report: Recommendations and Reports | 41.0 | 2 | 0 |
| Vital & health statistics. Series 3, Analytical and epidemiological studies | 41.0 | 2 | 0 |
| Vital and health statistics. Series 3, Analytical studies | 41.0 | 2 | 0 |
| Vital and health statistics. Ser. 4, Documents and committee reports | 41.0 | 2 | 0 |
| Vital and health statistics. Series 13, Data from the National Health Survey | 41.0 | 2 | 0 |
| Aging trends (Hyattsville, Md.) | 41.0 | 2 | 0 |
| NCHS data brief | 41.0 | 2 | 0 |
| MMWR supplements | 41.0 | 2 | 0 |
| National Center for Emerging and Zoonotic Infectious Diseases | 41.0 | 2 | 0 |
| Division of Parasitic Diseases and Malaria | 41.0 | 2 | 0 |
| Chronic Disease Prevention and Health Promotion | 41.0 | 2 | 0 |
| University of Miami Health System | 41.0 | 2 | 0 |
| Shady Grove Fertility Center | 41.0 | 2 | 0 |
| Cooper Health System | 41.0 | 2 | 0 |
| Baylor Scott & White Health | 41.0 | 2 | 0 |
| Fertility Centers of Illinois | 41.0 | 2 | 0 |
| New Hope Fertility Center | 41.0 | 2 | 0 |
| Johns Hopkins Medicine | 41.0 | 2 | 0 |
| The Hot Zone | 41.0 | 2 | 0 |
| Oncology Issues | 41.0 | 2 | 0 |
| Barkskins | 41.0 | 2 | 0 |
| Christopher R. Conley | 41.0 | 2 | 0 |
| Healthcare Infection Control Practices Advisory Committee | 41.0 | 2 | 0 |
| Progyny, Inc. | 41.0 | 2 | 0 |
| Vitrification (ovocytes) | 40.0 | 0 | 3 |
| fertility clinic | 40.0 | 0 | 3 |
| What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation? | 40.0 | 0 | 3 |
| Corifollitropin alfa compared to daily rFSH or HP-HMG in GnRH antagonist controlled ovarian stimulation protocol for patients undergoing assisted reproduction. | 40.0 | 0 | 3 |
| Ovarian tissue cryopreservation followed by controlled ovarian stimulation and pick-up of mature oocytes does not impair the number or quality of retrieved oocytes | 40.0 | 0 | 3 |
| Anti-Mullerian hormone and antral follicle count as predictors for embryo/oocyte cryopreservation cycle outcomes in breast cancer patients stimulated with letrozole and follicle stimulating hormone | 40.0 | 0 | 3 |
| Oocyte retrieval at 140-mmHg negative aspiration pressure: A promising alternative to flushing and aspiration in assisted reproduction in women with low ovarian reserve | 40.0 | 0 | 3 |
| Mature oocyte retrieval during laparotomic debulking surgery following random-start controlled ovarian stimulation for fertility preservation in a patient with suspected ovarian cancer | 40.0 | 0 | 3 |
| Comparison of anti-mullerian hormone and antral follicle count for assessment of ovarian reserve | 40.0 | 0 | 3 |
| The predictive value of anti-Mullerian hormone on embryo quality, blastocyst development, and pregnancy rate following in vitro fertilization-embryo transfer (IVF-ET). | 40.0 | 0 | 3 |
| Anti-mullerian hormone and antral follicle count as predictors of ovarian response in assisted reproduction | 40.0 | 0 | 3 |
| The correlation of the antral follicle count and Serum anti-mullerian hormone | 40.0 | 0 | 3 |
| Clinical recommendation on fertility preservation in borderline ovarian neoplasm: ovarian stimulation and oocyte retrieval after conservative surgery | 40.0 | 0 | 3 |
| Random Start Ovarian Stimulation for Oocyte or Embryo Cryopreservation in Women Desiring Fertility Preservation Prior to Gonadotoxic Cancer Therapy | 40.0 | 0 | 3 |
| Effect of smoking on ovarian reserve and ovarian stimulation in in- vitro fertilization and embryo transfer | 40.0 | 0 | 3 |
| In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation. | 40.0 | 0 | 3 |
| Comparison of antimüllerian hormone levels and antral follicle count as predictor of ovarian response to controlled ovarian stimulation in good-prognosis patients at individual fertility clinics in two multicenter trials | 40.0 | 0 | 3 |
| Fertility preservation by ovarian stimulation and oocyte cryopreservation in a 14-year-old adolescent with Turner syndrome mosaicism and impending premature ovarian failure | 40.0 | 0 | 3 |
| Effect of embryo freezing on perinatal outcome after assisted reproduction techniques: lessons from the Latin American Registry of Assisted Reproduction | 40.0 | 0 | 3 |
| Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen | 40.0 | 0 | 3 |
| Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation | 40.0 | 0 | 3 |
| The effect of elevated progesterone levels before oocyte retrieval in women undergoing ovarian stimulation for IVF treatment on the genomic profile of peri-implantation endometrium. | 40.0 | 0 | 3 |
| Nondominant small follicles are a promising source of mature oocytes in modified natural cycle in vitro fertilization and embryo transfer | 40.0 | 0 | 3 |
| Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcome of ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET | 40.0 | 0 | 3 |
| Predicting ovarian reserve and reproductive outcome using antimüllerian hormone (AMH) and antral follicle count (AFC) in patients with previous assisted reproduction technique (ART) failure | 40.0 | 0 | 3 |
| Selection of ovarian stimulation protocol is related to IVF treatment outcome in women 35 years of age and older | 40.0 | 0 | 3 |
| Luteal-phase ovarian stimulation increases the number of mature oocytes in older women with severe diminished ovarian reserve | 40.0 | 0 | 3 |
| Trust women to choose: a response to John a Robertson's 'Egg freezing and Egg banking: empowerment and alienation in assisted reproduction'. | 40.0 | 0 | 3 |
| Fertility preservation with random-start controlled ovarian stimulation and embryo cryopreservation for early pregnancy-associated breast cancer | 40.0 | 0 | 3 |
| Oocyte cryopreservation for future fertility: comparison of ovarian response between cancer and non-cancer patients | 40.0 | 0 | 3 |
| Laparoscopic Ovarian Cystectomy of Endometrioma vs Deroofing and Ovarian Reserve | 40.0 | 0 | 3 |
| Anti-Mullerian Hormone (AMH) Versus Antral Follicle Count (AFC) Guided rFSH Dosing Study | 40.0 | 0 | 3 |
| Anti-Mullerian Hormone (AMH) and Antral Follicle Count as Markers of Ovarian Reserve- Prospective Followup of Young Cancer Patients | 40.0 | 0 | 3 |
| Egg Freezing Pilot Study | 40.0 | 0 | 3 |
| Efficacy and Tolerance of an Ovarian Stimulation Protocol Combining Follicle Stimulating Hormone (FSH) and Degarelix Acetate in Female Candidates for Fertility Preservation Before Chemotherapy for Breast Cancer | 40.0 | 0 | 3 |
| Effect of Addition of Aromatase Inhibitor to Ovarian Stimulation Therapy in IVF Treatment | 40.0 | 0 | 3 |
| Prediction of ovarian reserve, poor response and pregnancy outcome based on basal antral follicle count and age in patients undergoing in vitro fertilization-embryo transfer | 40.0 | 0 | 3 |
| Fertility preservation in breast cancer patients by embryo cryopreservation after ovarian stimulation with letrozole and FSH | 40.0 | 0 | 3 |
| Role of baseline antral follicle count and anti-Mullerian hormone in the index stimulation cycle of IVF treatment in predicting outcome of subsequent frozen-thawed embryo transfers | 40.0 | 0 | 3 |
| Live birth rate comparison of three controlled ovarian stimulation protocols for in vitro fertilization-embryo transfer in patients with diminished ovarian reserve after endometrioma cystectomy: a retrospective study | 40.0 | 0 | 3 |
| Can delivery mode influence future ovarian reserve? Anti-Mullerian hormone levels and antral follicle count following cesarean section: a prospective cohort study | 40.0 | 0 | 3 |
| Effectiveness of the flexible progestin primed ovarian stimulation protocol compared to the flexible GnRH antagonist protocol in women with decreased ovarian reserve | 40.0 | 0 | 3 |
| Medroxyprogesterone acetate used in ovarian stimulation is associated with reduced mature oocyte retrieval and blastocyst development: a matched cohort study of 825 freeze-all IVF cycles | 40.0 | 0 | 3 |
| Anti-mullerian hormone level as a predictor of ovarian reserve in patients seeking fertility preservation versus infertility treatment | 40.0 | 0 | 3 |
| planned oocyte cryopreservation | 40.0 | 0 | 3 |
| GYN-FIV a.s. | 40.0 | 0 | 3 |
| assisted reproductive technology | 31.7 | 0 | 2 |
| Journal of Assisted Reproduction and Genetics | 31.7 | 0 | 2 |
| Reproductive Medicine and Biology | 31.7 | 0 | 2 |
| Post-embryo transfer interventions for assisted reproduction technology cycles | 31.7 | 0 | 2 |
| Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction | 31.7 | 0 | 2 |
| Pain relief for women undergoing oocyte retrieval for assisted reproduction | 31.7 | 0 | 2 |
| Tamoxifen or letrozole versus standard methods for women with estrogen-receptor positive breast cancer undergoing oocyte or embryo cryopreservation in assisted reproduction | 31.7 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles | 31.7 | 0 | 2 |
| Different ovarian stimulation protocols for women with diminished ovarian reserve | 31.7 | 0 | 2 |
| Journal of Experimental & Clinical Assisted Reproduction: shaping the future of research and practice in reproductive endocrinology/infertility | 31.7 | 0 | 2 |
| Anti-Mullerian Hormone: Above and Beyond Conventional Ovarian Reserve Markers | 31.7 | 0 | 2 |
| Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice | 31.7 | 0 | 2 |
| Myocardial infarction complicating the initial phase of an ovarian stimulation protocol | 31.7 | 0 | 2 |
| Prevention of chemotherapy-induced ovarian damage: possible roles for hormonal and non-hormonal attenuating agents | 31.7 | 0 | 2 |
| Q28344605 | 31.7 | 0 | 2 |
| Increased count, motility, and total motile sperm cells collected across three consecutive ejaculations within 24 h of oocyte retrieval: implications for management of men presenting with low numbers of motile sperm for assisted reproduction | 31.7 | 0 | 2 |
| Assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial: baseline characteristics | 31.7 | 0 | 2 |
| Predictors of pregnancy and live-birth in couples with unexplained infertility after ovarian stimulation-intrauterine insemination | 31.7 | 0 | 2 |
| Safety issues in assisted reproduction technology. From theory to reality--just what are the data telling us about ICSI offspring health and future fertility and should we be concerned? | 31.7 | 0 | 2 |
| Live birth after fresh embryo transfer vs elective embryo cryopreservation/frozen embryo transfer in women with polycystic ovary syndrome undergoing IVF (FreFro-PCOS): study protocol for a multicenter, prospective, randomized controlled clinical tri | 31.7 | 0 | 2 |
| Assisted reproduction-in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues | 31.7 | 0 | 2 |
| Analysis of oocyte cryopreservation in assisted reproduction: the Italian National Register data from 2005 to 2007 | 31.7 | 0 | 2 |
| Follicle-stimulating hormone and human menopausal gonadotropin for ovarian stimulation in assisted reproduction cycles | 31.7 | 0 | 2 |
| Ovarian reserve tests and their utility in predicting response to controlled ovarian stimulation in rhesus monkeys | 31.7 | 0 | 2 |
| Antral follicle count in normal (fertility-proven) and infertile Indian women | 31.7 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. | 31.7 | 0 | 2 |
| How the FMR1 gene became relevant to female fertility and reproductive medicine | 31.7 | 0 | 2 |
| Minimal ovarian stimulation (mini-IVF) for IVF utilizing vitrification and cryopreserved embryo transfer | 31.7 | 0 | 2 |
| Ovarian stimulation during the luteal phase for fertility preservation of cancer patients: case reports and review of the literature | 31.7 | 0 | 2 |
| Oocyte cryopreservation: a feasible fertility preservation option for reproductive age cancer survivors. | 31.7 | 0 | 2 |
| The effect of progesterone level prior to oocyte retrieval on the numbers of oocytes retrieved and embryo quality in IVF treatment cycles: an analysis of 2,978 cycles | 31.7 | 0 | 2 |
| Human cleavage-stage embryo vitrification is comparable to slow-rate cryopreservation in cycles of assisted reproduction | 31.7 | 0 | 2 |
| Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011. | 31.7 | 0 | 2 |
| Ovarian response and cumulative live birth rate of women undergoing in-vitro fertilisation who had discordant anti-Mullerian hormone and antral follicle count measurements: a retrospective study. | 31.7 | 0 | 2 |
| Anti-Müllerian Hormone Serum Values and Ovarian Reserve: Can It Predict a Decrease in Fertility after Ovarian Stimulation by ART Cycles? | 31.7 | 0 | 2 |
| Risk of thrombosis in women with malignancies undergoing ovarian stimulation for fertility preservation | 31.7 | 0 | 2 |
| A minimally monitored assisted reproduction stimulation protocol reduces cost without compromising success | 31.7 | 0 | 2 |
| Embryo cryopreservation in a case of acute promyelocytic leukemia, incidentally diagnosed during ovarian stimulation for in-vitro fertilization | 31.7 | 0 | 2 |
| Anti-Mullerian Hormone: A Marker of Ovarian Reserve and its Association with Polycystic Ovarian Syndrome | 31.7 | 0 | 2 |
| Updated meta-analysis of recombinant follicle-stimulating hormone (FSH) versus urinary FSH for ovarian stimulation in assisted reproduction | 31.7 | 0 | 2 |
| Testing for Ovarian Reserve in Assisted Reproduction programs: the current point of view | 31.7 | 0 | 2 |
| Oocyte Cryopreservation for Fertility Preservation in Postpubertal Female Children at Risk for Premature Ovarian Failure Due to Accelerated Follicle Loss in Turner Syndrome or Cancer Treatments | 31.7 | 0 | 2 |
| The impact of endometrioma and laparoscopic cystectomy on ovarian reserve and the exploration of related factors assessed by serum anti-Mullerian hormone: a prospective cohort study | 31.7 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons: a committee opinion | 31.7 | 0 | 2 |
| Role of baseline antral follicle count and anti-Mullerian hormone in prediction of cumulative live birth in the first in vitro fertilisation cycle: a retrospective cohort analysis. | 31.7 | 0 | 2 |
| Pronuclear embryo cryopreservation experience: outcomes for reducing the risk of ovarian hyperstimulation syndrome and for fertility preservation in cancer patients | 31.7 | 0 | 2 |
| Chronological age vs biological age: an age-related normogram for antral follicle count, FSH and anti-Mullerian hormone. | 31.7 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile | 31.7 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons | 31.7 | 0 | 2 |
| Comparison of pregnancy outcome after letrozole versus clomiphene treatment for mild ovarian stimulation protocol in poor responders | 31.7 | 0 | 2 |
| Ovarian stimulation in patients with breast cancer | 31.7 | 0 | 2 |
| The correlations of anti-mullerian hormone, follicle-stimulating hormone and antral follicle count in different age groups of infertile women | 31.7 | 0 | 2 |
| Ovarian stimulation and in-vitro fertilization outcomes of cancer patients undergoing fertility preservation compared to age matched controls: a 17-year experience | 31.7 | 0 | 2 |
| Evidence to Incorporate Inclusive Reproductive Health Measures in Guidelines for Childhood and Adolescent Cancer Survivors | 31.7 | 0 | 2 |
| Thromboembolism after ovarian stimulation: successful management of a woman with superior sagittal sinus thrombosis after IVF and embryo transfer: Case report | 31.7 | 0 | 2 |
| Choice of ovarian stimulation regimens in assisted reproduction: finding the thread in the gonadotropin maze | 31.7 | 0 | 2 |
| Ovarian stimulation for emergency fertility preservation in cancer patients: A case series study | 31.7 | 0 | 2 |
| The Management of Uterine Fibroids in Women With Otherwise Unexplained Infertility | 31.7 | 0 | 2 |
| Optimal timing for elective egg freezing | 31.7 | 0 | 2 |
| Human oocyte cryopreservation: a valid alternative to embryo cryopreservation? | 31.7 | 0 | 2 |
| Ovarian stimulation and embryo banking for fertility preservation in a woman with severe mixed connective tissue disease: is it safe? | 31.7 | 0 | 2 |
| Is ABO blood type associated with ovarian stimulation response in patients with diminished ovarian reserve? | 31.7 | 0 | 2 |
| What is the most relevant standard of success in assisted reproduction? Redefining success in the context of elective single embryo transfer: evidence, intuition and financial reality | 31.7 | 0 | 2 |
| Fertility Preservation Success Subsequent to Concurrent Aromatase Inhibitor Treatment and Ovarian Stimulation in Women With Breast Cancer | 31.7 | 0 | 2 |
| Luteal phase ovarian stimulation following oocyte retrieval: is it helpful for poor responders? | 31.7 | 0 | 2 |
| Ovarian tissue and oocyte cryopreservation | 31.7 | 0 | 2 |
| Oocyte retrieval following continued stimulation five days beyond ovulation yields live birth after frozen embryo transfer | 31.7 | 0 | 2 |
| Oocyte versus embryo cryopreservation for fertility preservation in cancer patients: guaranteeing a women's autonomy | 31.7 | 0 | 2 |
| Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation | 31.7 | 0 | 2 |
| Anti-Mullerian hormone as a predictor of ovarian reserve in ART protocols: the hidden role of thyroid autoimmunity | 31.7 | 0 | 2 |
| Minimal ovarian stimulation combined with elective single embryo transfer policy: age-specific results of a large, single-centre, Japanese cohort | 31.7 | 0 | 2 |
| The association of serum estradiol level with outcomes of clomiphene citrate/human menopausal gonadotropin ovarian stimulation for in vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Outcomes of ovarian stimulation after treatment with chemotherapy | 31.7 | 0 | 2 |
| Use of anti-mullerian hormone for testing ovarian reserve: a survey of 796 infertility clinics worldwide | 31.7 | 0 | 2 |
| Measurement of antral follicle count in patients undergoing in vitro fertilization treatment: results of a worldwide web-based survey | 31.7 | 0 | 2 |
| Soft versus firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis | 31.7 | 0 | 2 |
| Follicular fluid insulin-like growth factor-I and insulin-like growth factor-binding protein-1 and -3 vary as a function of ovarian reserve and ovarian stimulation | 31.7 | 0 | 2 |
| Conservative management versus aspiration of functional ovarian cysts before ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| The added value of embryo cryopreservation to cumulative ongoing pregnancy rates per IVF treatment: is cryopreservation worth the effort? | 31.7 | 0 | 2 |
| A global perspective on assisted reproductive technology fertility treatment: an 8-country fertility specialist survey | 31.7 | 0 | 2 |
| Anti-mullerian hormone cut-off values for predicting poor ovarian response to exogenous ovarian stimulation in in-vitro fertilization | 31.7 | 0 | 2 |
| Firm embryo transfer catheters for assisted reproduction: a systematic review and meta-analysis using direct and adjusted indirect comparisons | 31.7 | 0 | 2 |
| Oncofertility: a grand collaboration between reproductive medicine and oncology | 31.7 | 0 | 2 |
| Age-Related Normogram for Ovarian Antral Follicle Count in Women with Polycystic Ovary Syndrome and Comparison with Age Matched Controls Using Magnetic Resonance Imaging | 31.7 | 0 | 2 |
| Guidelines for reducing the risk of viral transmission during fertility treatment | 31.7 | 0 | 2 |
| The role of fertility preservation in patients with endometriosis | 31.7 | 0 | 2 |
| Oncofertility: combination of ovarian stimulation with subsequent ovarian tissue extraction on the day of oocyte retrieval | 31.7 | 0 | 2 |
| Reluctance of medical professionals in adopting natural-cycle and minimal ovarian stimulation protocols in human clinical assisted reproduction | 31.7 | 0 | 2 |
| Random-start controlled ovarian stimulation for emergency fertility preservation in a patient with myelodysplastic syndrome: a case report | 31.7 | 0 | 2 |
| Female patients with lymphoma demonstrate diminished ovarian reserve even before initiation of chemotherapy when compared with healthy controls and patients with other malignancies | 31.7 | 0 | 2 |
| Use of letrozole in assisted reproduction: a systematic review and meta-analysis. | 31.7 | 0 | 2 |
| Ovarian hyperstimulation syndrome and prophylactic human embryo cryopreservation: analysis of reproductive outcome following thawed embryo transfer | 31.7 | 0 | 2 |
| Estimating rates of multiple gestation pregnancies: sample size calculation from the assessment of multiple intrauterine gestations from ovarian stimulation (AMIGOS) trial | 31.7 | 0 | 2 |
| The effectiveness of earlier oocyte retrieval in the case of a premature luteinizing hormone surge on hCG day in in vitro fertilization-embryo transfer cycles | 31.7 | 0 | 2 |
| Comparison of the GnRH agonist and antagonist protocol on the same patients in assisted reproduction during controlled ovarian stimulation cycles | 31.7 | 0 | 2 |
| "Anti-Mullerian Hormone: Marker for Ovarian Response in Controlled Ovarian Stimulation for IVF Patients": A First Pilot Study in the Indian Population | 31.7 | 0 | 2 |
| AMH type II receptor and AMH gene polymorphisms are not associated with ovarian reserve, response, or outcomes in ovarian stimulation. | 31.7 | 0 | 2 |
| Egg freezing and egg banking: empowerment and alienation in assisted reproduction | 31.7 | 0 | 2 |
| Determining an anti-mullerian hormone cutoff level to predict clinical pregnancy following in vitro fertilization in women with severely diminished ovarian reserve | 31.7 | 0 | 2 |
| Present and future fertility preservation strategies for female cancer patients | 31.7 | 0 | 2 |
| Assisted reproduction and fertility preservation techniques in cancer patients | 31.7 | 0 | 2 |
| Optimizing natural fertility | 31.7 | 0 | 2 |
| Blastocyst culture and transfer in clinical-assisted reproduction | 31.7 | 0 | 2 |
| Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles | 31.7 | 0 | 2 |
| Improving the patient's experience of IVF/ICSI: a proposal for an ovarian stimulation protocol with GnRH antagonist co-treatment | 31.7 | 0 | 2 |
| Anti-Müllerian hormone and antral follicle count reveal a late impairment of ovarian reserve in patients undergoing low-gonadotoxic regimens for hematological malignancies | 31.7 | 0 | 2 |
| Endometrial signaling pathways during ovarian stimulation for assisted reproduction technology | 31.7 | 0 | 2 |
| Twenty-five-year-old Woman with Bilateral Borderline Ovarian Tumour Desiring to Preserve Fertility - Case Report and Literature Review on the Current State of Fertility Preservation in Women with Borderline Ovarian Tumours | 31.7 | 0 | 2 |
| Fertility Preservation Options after Gonadotoxic Chemotherapy | 31.7 | 0 | 2 |
| Safety and feasibility of performing two consecutive ovarian stimulation cycles with the use of letrozole-gonadotropin protocol for fertility preservation in breast cancer patients | 31.7 | 0 | 2 |
| Assessment of ovarian reserve: Anti-Mullerian hormone versus follicle stimulating hormone | 31.7 | 0 | 2 |
| Reproductive planning in times of Zika: getting pregnant or delaying plans? The opinion of the Brazilian Society of Assisted Reproduction Committee - a basis for a bioethical discussion | 31.7 | 0 | 2 |
| Anti-mullerian hormone as a predictor of ovarian reserve and ovarian response in IVF women from Gaza strip | 31.7 | 0 | 2 |
| Ovarian reserve and subsequent assisted reproduction outcomes after methotrexate therapy for ectopic pregnancy or pregnancy of unknown location | 31.7 | 0 | 2 |
| Current approach to fertility preservation by embryo cryopreservation | 31.7 | 0 | 2 |
| Fertility-Preserving Treatment Options in Patients with Malignant Hematological Diseases | 31.7 | 0 | 2 |
| Luteal phase oocyte retrieval and in vitro maturation is an optional procedure for urgent fertility preservation | 31.7 | 0 | 2 |
| The promise of in vitro maturation in assisted reproduction and fertility preservation. | 31.7 | 0 | 2 |
| Oocyte cryopreservation as a fertility preservation measure for cancer patients | 31.7 | 0 | 2 |
| Oocyte cryopreservation for donor egg banking | 31.7 | 0 | 2 |
| Corifollitropin alfa: a review of its use in controlled ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| Elective single-embryo transfer | 31.7 | 0 | 2 |
| Does exogenous LH in ovarian stimulation improve assisted reproduction success? An appraisal of the literature | 31.7 | 0 | 2 |
| Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer | 31.7 | 0 | 2 |
| Oogonial stem cells: do they exist and may they have an impact on future fertility treatment? | 31.7 | 0 | 2 |
| Blastocyst culture and transfer in clinical-assisted reproduction: a committee opinion | 31.7 | 0 | 2 |
| The wobbly evidence base of reproductive medicine | 31.7 | 0 | 2 |
| Freezing the biological clock: a viable fertility preservation option for young Singapore women? | 31.7 | 0 | 2 |
| Aspects of in vivo oocyte production, blastocyst development, and embryo transfer in the cat | 31.7 | 0 | 2 |
| Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients | 31.7 | 0 | 2 |
| Misconduct in third-party assisted reproduction: a committee opinion | 31.7 | 0 | 2 |
| Clinical rationale for cryopreservation of entire embryo cohorts in lieu of fresh transfer | 31.7 | 0 | 2 |
| The effect of surgery for endometrioma on ovarian reserve evaluated by antral follicle count: a systematic review and meta-analysis. | 31.7 | 0 | 2 |
| AMH: An ovarian reserve biomarker in assisted reproduction. | 31.7 | 0 | 2 |
| Methods employed to overcome difficult embryo transfer during assisted reproduction treatment | 31.7 | 0 | 2 |
| Optimal Oocyte Retrieval and Embryo Transfer Techniques: Where We Are and How We Got Here | 31.7 | 0 | 2 |
| Comparison of ultrasound-guided endometrial polypectomy carried out on the oocyte retrieval day and the first day of ovarian stimulation in IVF-ICSI cycles | 31.7 | 0 | 2 |
| Evidence of impaired endometrial receptivity after ovarian stimulation for in vitro fertilization: a prospective randomized trial comparing fresh and frozen–thawed embryo transfer in normal responders | 31.7 | 0 | 2 |
| Comparison of follicular fluid IGF-I, IGF-II, IGFBP-3, IGFBP-4 and PAPP-A concentrations and their ratios between GnRH agonist and GnRH antagonist protocols for controlled ovarian stimulation in IVF-embryo transfer patients | 31.7 | 0 | 2 |
| Shifting Paradigms in Diminished Ovarian Reserve and Advanced Reproductive Age in Assisted Reproduction: Customization Instead of Conformity | 31.7 | 0 | 2 |
| Subclinical hypothyroidism in the infertile female population: a guideline | 31.7 | 0 | 2 |
| Fertility Preservation in Women with Ovarian Endometriosis | 31.7 | 0 | 2 |
| Molecular aspects and clinical methods for preserving ovarian reserves in women receiving cancer treatment | 31.7 | 0 | 2 |
| What women want? A scoping survey on women's knowledge, attitudes and behaviours towards ovarian reserve testing and egg freezing. | 31.7 | 0 | 2 |
| BRCA1 mutation carriers have a lower number of mature oocytes after ovarian stimulation for IVF/PGD. | 31.7 | 0 | 2 |
| Comparison of neonatal outcomes following progesterone use during ovarian stimulation with frozen-thawed embryo transfer | 31.7 | 0 | 2 |
| Ovarian Stimulation Protocol in IVF: An Up-to-Date Review of the Literature | 31.7 | 0 | 2 |
| Urinary triclosan concentrations and diminished ovarian reserve among women undergoing treatment in a fertility clinic | 31.7 | 0 | 2 |
| The effect of peri-implantation administration of uterine relaxing agents in assisted reproduction treatment cycles: a systematic review and meta-analysis | 31.7 | 0 | 2 |
| Oocyte vitrification for elective fertility preservation: the past, present, and future | 31.7 | 0 | 2 |
| Mature Oocyte Cryopreservation for Fertility Preservation | 31.7 | 0 | 2 |
| Assessment of ovarian reserve and fertility preservation strategies in children treated for cancer. | 31.7 | 0 | 2 |
| Fertility preservation in female oncology patients: the influence of the type of cancer on ovarian stimulation response | 31.7 | 0 | 2 |
| Embryo transfer techniques: an American Society for Reproductive Medicine survey of current Society for Assisted Reproductive Technology practices | 31.7 | 0 | 2 |
| EXPRESSION OF CONCERN: Addition of growth hormone to the microflare stimulation protocol among women with poor ovarian response | 31.7 | 0 | 2 |
| Embryo transfer simulation improves pregnancy rates and decreases time to proficiency in Reproductive Endocrinology and Infertility fellow embryo transfers | 31.7 | 0 | 2 |
| Fertility Preservation Options for Men and Women With Cancer | 31.7 | 0 | 2 |
| The cutoff values of serum AMH levels and starting recFSH doses for the individualization of IVF treatment strategies | 31.7 | 0 | 2 |
| Emergent Oocyte Cryopreservation with a Novel Ovarian Transposition Technique in a Colorectal Cancer Patient: A Combined Approach for Fertility Preservation. A Case Report | 31.7 | 0 | 2 |
| Oocyte cryopreservation for fertility preservation in women with cancer | 31.7 | 0 | 2 |
| Outcome, complications and future fertility in women treated with uterine artery embolization and methotrexate for non-tubal ectopic pregnancy | 31.7 | 0 | 2 |
| 'Banking time': egg freezing and the negotiation of future fertility | 31.7 | 0 | 2 |
| Individualization of controlled ovarian stimulation in vitro fertilization using ovarian reserve markers | 31.7 | 0 | 2 |
| A mild ovarian stimulation strategy in women with poor ovarian reserve undergoing IVF: a multicenter randomized non-inferiority trial | 31.7 | 0 | 2 |
| Performing the embryo transfer: a guideline | 31.7 | 0 | 2 |
| Genetics of gonadotropins and their receptors as markers of ovarian reserve and response in controlled ovarian stimulation | 31.7 | 0 | 2 |
| Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion | 31.7 | 0 | 2 |
| Comparison of serum anti-mullerian hormone among fertile and infertile normal and diminished ovarian reserve groups | 31.7 | 0 | 2 |
| What do reproductive-age women who undergo oocyte cryopreservation think about the process as a means to preserve fertility? | 31.7 | 0 | 2 |
| The case for aromatase inhibitors use in Oncofertility patients. Should aromatase inhibitors be combined with gonadotropin treatment in Breast Cancer patients undergoing ovarian stimulation for fertility preservation prior to chemotherapy? A debate | 31.7 | 0 | 2 |
| Low AMH levels as a marker of reduced ovarian reserve in young women affected by Down's syndrome. | 31.7 | 0 | 2 |
| Couples with unexplained subfertility and unfavorable prognosis: a randomized pilot trial comparing the effectiveness of in vitro fertilization with elective single embryo transfer versus intrauterine insemination with controlled ovarian stimulation | 31.7 | 0 | 2 |
| A clinical dilemma: the potential use of egg freezing to preserve fertility in a young patient at risk of developing premature ovarian failure | 31.7 | 0 | 2 |
| Ovarian stimulation with clomiphene and/or human menopausal gonadotropin (HMG) for in vitro fertilization (IVF) and embryo transfer (ET). | 31.7 | 0 | 2 |
| Assisted reproductive medicine in Poland --Fertility and Sterility Special Interest Group of the Polish Gynaecological Society (SPiN PTG) 2012 report | 31.7 | 0 | 2 |
| Timing of breast cancer treatments with oocyte retrieval and embryo cryopreservation | 31.7 | 0 | 2 |
| Luteal-phase ovarian stimulation is a feasible method for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment compared to a GnRH antagonist protocol: A retrospective study | 31.7 | 0 | 2 |
| Clinical outcomes of frozen-thawed single blastocyst transfer in patients requiring whole embryo freezing | 31.7 | 0 | 2 |
| Does controlled ovarian stimulation prior to chemotherapy increase primordial follicle loss and diminish ovarian reserve? An animal study | 31.7 | 0 | 2 |
| Catastrophic payment for assisted reproduction techniques with conventional ovarian stimulation in the public health sector of South Africa: frequency and coping strategies | 31.7 | 0 | 2 |
| Conventional ovarian stimulation and single embryo transfer for IVF/ICSI. How many oocytes do we need to maximize cumulative live birth rates after utilization of all fresh and frozen embryos? | 31.7 | 0 | 2 |
| Assisted reproduction policies in Israel: a retrospective analysis of in vitro fertilization–embryo transfer | 31.7 | 0 | 2 |
| Letrozole for ovulation induction and fertility preservation by embryo cryopreservation in young women with endometrial carcinoma | 31.7 | 0 | 2 |
| Assessment of ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with familial Mediterranean fever | 31.7 | 0 | 2 |
| Luteal‐phase ovarian stimulation vs conventional ovarian stimulation in patients with normal ovarian reserve treated for IVF: a large retrospective cohort study | 31.7 | 0 | 2 |
| Specific ranges of anti-Mullerian hormone and antral follicle count correlate to provide a prognostic indicator for IVF outcome | 31.7 | 0 | 2 |
| Association of uterine fibroids and pregnancy outcomes after ovarian stimulation-intrauterine insemination for unexplained infertility. | 31.7 | 0 | 2 |
| Is there an effect of thyroid autoimmunity on the outcomes of assisted reproduction? | 31.7 | 0 | 2 |
| Fertility preservation and reproduction in cancer patients | 31.7 | 0 | 2 |
| A survey of Irish consultants regarding awareness of sperm freezing and assisted reproduction. | 31.7 | 0 | 2 |
| Cycle-to-cycle variation in utero-ovarian hemodynamic indices in ovarian stimulation and natural cycles of the same women and its effect on the outcome of assisted reproduction treatment. | 31.7 | 0 | 2 |
| Comparing four ovarian reserve markers--associations with ovarian response and live births after assisted reproduction | 31.7 | 0 | 2 |
| Luteinizing hormone-releasing hormone agonists for ovarian stimulation in assisted reproduction | 31.7 | 0 | 2 |
| Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction | 31.7 | 0 | 2 |
| Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients. | 31.7 | 0 | 2 |
| Ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| Effect of Methotrexate or Salpingectomy for Ectopic Pregnancy on Subsequent In Vitro Fertilization–Embryo Transfer Outcomes | 31.7 | 0 | 2 |
| Mole modifications following controlled ovarian stimulation for assisted reproduction technologies | 31.7 | 0 | 2 |
| Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles | 31.7 | 0 | 2 |
| Impact of single embryo transfer policy on perinatal outcomes in fresh and frozen cycles—analysis of the Japanese Assisted Reproduction Technology registry between 2007 and 2012 | 31.7 | 0 | 2 |
| Ovarian stimulation in assisted reproduction. | 31.7 | 0 | 2 |
| Testing and interpreting measures of ovarian reserve: a committee opinion | 31.7 | 0 | 2 |
| Embryo Cryopreservation Following In-Vitro Maturation for Fertility Preservation in a Woman with Mullerian Adenosarcoma: A Case Report | 31.7 | 0 | 2 |
| Freeze-all, oocyte vitrification, or fresh embryo transfer? Lessons from an egg-sharing donation program | 31.7 | 0 | 2 |
| Concurrent oocyte retrieval and hysteroscopy: a novel approach in assisted reproduction freeze-all cycles. | 31.7 | 0 | 2 |
| Oocyte vitrification for elective fertility preservation: lessons for patient counseling | 31.7 | 0 | 2 |
| FERTILITY PRESERVATION OF WOMEN: OOCYTE VITRIFICATION | 31.7 | 0 | 2 |
| Oocyte vitrification as an efficient option for elective fertility preservation | 31.7 | 0 | 2 |
| Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval | 31.7 | 0 | 2 |
| Obstetric outcome after oocyte vitrification and warming for fertility preservation in women with cancer. | 31.7 | 0 | 2 |
| Oocyte versus embryo vitrification for delayed embryo transfer: an observational study | 31.7 | 0 | 2 |
| The Russian experience of autotransplantation of vitrified ovarian tissue to a cancer patient | 31.7 | 0 | 2 |
| Practical clinical aspects of oocyte vitrification for fertility preservation | 31.7 | 0 | 2 |
| Five years' experience using oocyte vitrification to preserve fertility for medical and nonmedical indications | 31.7 | 0 | 2 |
| Oocyte vitrification in a single woman with diminished ovarian reserve resulting in live birth | 31.7 | 0 | 2 |
| Oocyte vitrification and its impact on the clinical practice of assisted reproduction | 31.7 | 0 | 2 |
| Mature oocyte cryopreservation: a guideline | 31.7 | 0 | 2 |
| Neonatal outcome and birth defects in 6623 singletons born following minimal ovarian stimulation and vitrified versus fresh single embryo transfer | 31.7 | 0 | 2 |
| Effects of cryopreservation time and thawing method of human oocyte vitrification on the outcome of assisted reproduction | 31.7 | 0 | 2 |
| Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification | 31.7 | 0 | 2 |
| New options in assisted reproduction technology: the Cryotop method of oocyte vitrification | 31.7 | 0 | 2 |
| Lapse in embryo transfer training does not negatively affect clinical pregnancy rates for reproductive endocrinology and infertility fellows | 31.7 | 0 | 2 |
| Sibling embryo blastocyst development correlates with the in vitro fertilization day 3 embryo transfer pregnancy rate in patients under age 40. | 31.7 | 0 | 2 |
| Ovarian stimulation and corpus luteum function in human in vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Preprogrammed, unmonitored ovarian stimulation reduces expense without compromising the outcome of assisted reproduction | 31.7 | 0 | 2 |
| Viability of cumulus cells is associated with basal AMH levels in assisted reproduction. | 31.7 | 0 | 2 |
| Day-5 inhibin B serum concentrations and antral follicle count as predictors of ovarian response and live birth in assisted reproduction cycles stimulated with gonadotropin after pituitary suppression | 31.7 | 0 | 2 |
| Prospective evaluation of basal stromal Doppler studies in women with good ovarian reserve and infertility undergoing in vitro fertilization-embryo transfer treatment: patients with polycystic ovary syndrome versus ovulatory patients. | 31.7 | 0 | 2 |
| Anti-Mullerian hormone is a better marker than inhibin B, follicle stimulating hormone, estradiol or antral follicle count in predicting the outcome of in vitro fertilization | 31.7 | 0 | 2 |
| Performance of different ovarian reserve markers for predicting the numbers of oocytes retrieved and mature oocytes | 31.7 | 0 | 2 |
| Delivery rates following IVF treatment, using two recombinant FSH preparations for ovarian stimulation | 31.7 | 0 | 2 |
| IVF Treatment and Single Embryo Transfer | 31.7 | 0 | 2 |
| First French live-birth after oocyte vitrification performed before chemotherapy for fertility preservation | 31.7 | 0 | 2 |
| Serum anti-Mullerian hormone is a useful measure of quantitative ovarian reserve but does not predict the chances of live-birth pregnancy | 31.7 | 0 | 2 |
| Clinical Utility of Measurement of Anti-Müllerian Hormone in Reproductive Endocrinology | 31.7 | 0 | 2 |
| Do ovarian reserve tests predict miscarriage in women undergoing assisted reproduction treatment? | 31.7 | 0 | 2 |
| A randomised controlled trial of 300 versus 225 IU recombinant FSH for ovarian stimulation in predicted normal responders by antral follicle count | 31.7 | 0 | 2 |
| Myotonic dystrophy type 1 and PGD: ovarian stimulation response and correlation analysis between ovarian reserve and genotype | 31.7 | 0 | 2 |
| Ovarian stimulation and emergency in vitro fertilization for fertility preservation in cancer patients | 31.7 | 0 | 2 |
| Oocyte cryopreservation after controlled ovarian hyperstimulation in mosaic Turner syndrome: another fertility preservation option in a dedicated UK clinic | 31.7 | 0 | 2 |
| The cohort of antral follicles measuring 2-6 mm reflects the quantitative status of ovarian reserve as assessed by serum levels of anti-Müllerian hormone and response to controlled ovarian stimulation | 31.7 | 0 | 2 |
| First live birth following IVF-embryo transfer and use of GnRHa alone for ovarian stimulation | 31.7 | 0 | 2 |
| Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin-releasing hormone agonist and antagonists, on follicular fluid stem cell factor and serum urocortin 1 levels on the day of oocyte retrieval | 31.7 | 0 | 2 |
| Refuting a misguided campaign against the goal of single-embryo transfer and singleton birth in assisted reproduction | 31.7 | 0 | 2 |
| Cystic fibrosis (cf) and ovarian reserve: A cross-sectional study examining serum anti-mullerian hormone (amh) in young women | 31.7 | 0 | 2 |
| Frozen-thawed embryo transfer and live birth: Long-term follow-up after one oocyte retrieval | 31.7 | 0 | 2 |
| Optimizing natural fertility: a committee opinion | 31.7 | 0 | 2 |
| Life after unsuccessful IVF treatment in an assisted reproduction unit: a qualitative analysis of gains through loss among Chinese persons in Hong Kong. | 31.7 | 0 | 2 |
| Suppression of LH during ovarian stimulation: analysing threshold values and effects on ovarian response and the outcome of assisted reproduction in down-regulated women stimulated with recombinant FSH. | 31.7 | 0 | 2 |
| Increased progesterone/estradiol ratio in the late follicular phase could be related to low ovarian reserve in in vitro fertilization-embryo transfer cycles with a long gonadotropin-releasing hormone agonist | 31.7 | 0 | 2 |
| Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion | 31.7 | 0 | 2 |
| Impact of pituitary suppression on antral follicle count and oocyte recovery after ovarian stimulation | 31.7 | 0 | 2 |
| Ovarian stimulation and ultrasound-guided oocyte retrieval in baboon (Papio Cynocephalus Anubis) during pituitary suppression with a GnRH agonist. | 31.7 | 0 | 2 |
| The relationship between endogenous oestradiol and vitamin D3 metabolites in serum and follicular fluid during ovarian stimulation for in-vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Personal experience with ovarian stimulation in an in vitro fertilization and embryo transfer program | 31.7 | 0 | 2 |
| The serum concentration of estradiol after embryo transfer and the decline from preovulatory levels may influence the success of IVF treatment | 31.7 | 0 | 2 |
| Assisted fertilization. Clinical studies with particular attention to ovarian stimulation, oocyte retrieval and transfer of gametes or embryos | 31.7 | 0 | 2 |
| Human oocyte cryopreservation as an adjunct to IVF-embryo transfer cycles | 31.7 | 0 | 2 |
| Timing of Oocyte Retrieval and Embryo Transfer with Pregnancy Duration | 31.7 | 0 | 2 |
| LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH. | 31.7 | 0 | 2 |
| Effect of ovarian stimulation on plasma lipid and apolipoprotein concentrations in a population of infertile women undergoing IVF/embryo transfer | 31.7 | 0 | 2 |
| Concentrations of gonadotrophins and steroids in pre-ovulatory follicular fluid and serum in relation to stimulation protocol and outcome of assisted reproduction treatment | 31.7 | 0 | 2 |
| Is there any place for oocyte cryopreservation after cancer treatment? | 31.7 | 0 | 2 |
| IVF with planned single-embryo transfer versus IUI with ovarian stimulation in couples with unexplained subfertility: an economic analysis | 31.7 | 0 | 2 |
| Ovarian stimulation for in vitro fertilization and embryo transfer, human menopausal gonadotropin versus pure human follicle stimulating hormone: a randomized prospective study. | 31.7 | 0 | 2 |
| Half-dose depot triptorelin in pituitary suppression for multiple ovarian stimulation in assisted reproduction technology: a randomized study | 31.7 | 0 | 2 |
| Embryo transfer by reproductive endocrinology fellows vs attending physicians: are live birth rates comparable? | 31.7 | 0 | 2 |
| Comparison of clinical outcome of mild-stimulation and conventional ovarian stimulation in in vitro fertilization-embryo transfer (IVF-ET) | 31.7 | 0 | 2 |
| Effect of pituitary downregulation on antral follicle count, ovarian volume and stromal blood flow measured by three-dimensional ultrasound with power Doppler prior to ovarian stimulation | 31.7 | 0 | 2 |
| Perspective on in vitro fertilization and embryo transfer. Stimulus for biomedical research in reproductive medicine | 31.7 | 0 | 2 |
| Risk-sharing or refund programs in assisted reproduction: a committee opinion | 31.7 | 0 | 2 |
| Optimizing human oocyte cryopreservation for fertility preservation patients: should we mature then freeze or freeze then mature? | 31.7 | 0 | 2 |
| Expected poor responders on the basis of an antral follicle count do not benefit from a higher starting dose of gonadotrophins in IVF treatment: a randomized controlled trial | 31.7 | 0 | 2 |
| Preovulatory follicular fluid: relationships to ovarian stimulation protocol, fertilization, and sperm penetration in vitro | 31.7 | 0 | 2 |
| Anti-Müllerian hormone and antral follicle count for prediction of ovarian stimulation response in polycystic ovary syndrome. | 31.7 | 0 | 2 |
| Anti-mullerian hormone as a marker of ovarian reserve | 31.7 | 0 | 2 |
| Antral follicle count and FSH concentration after clomiphene citrate challenge test in the prediction of ovarian response during IVF treatment | 31.7 | 0 | 2 |
| First pregnancy and live birth resulting from cryopreserved embryos obtained from in vitro matured oocytes after oophorectomy in an ovarian cancer patient | 31.7 | 0 | 2 |
| Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation | 31.7 | 0 | 2 |
| Complications related to ovarian stimulation and oocyte retrieval in 4052 oocyte donor cycles | 31.7 | 0 | 2 |
| Response to 'Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors?'. | 31.7 | 0 | 2 |
| Anti-Mullerian hormone (AMH): what do we still need to know? | 31.7 | 0 | 2 |
| The Impact of Adnexal Torsion on Antral Follicle Count when Compared With Contralateral Ovary | 31.7 | 0 | 2 |
| Leuprolide acetate lowers circulating bioactive luteinizing hormone and testosterone concentrations during ovarian stimulation for oocyte retrieval | 31.7 | 0 | 2 |
| Public policy aspects of assisted reproduction. Vth World Congress, IVF and embryo transfer | 31.7 | 0 | 2 |
| Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval | 31.7 | 0 | 2 |
| A GnRH agonist and exogenous hormone stimulation protocol has a higher live-birth rate than a natural endogenous hormone protocol for frozen-thawed blastocyst-stage embryo transfer cycles: an analysis of 1391 cycles | 31.7 | 0 | 2 |
| Effect of ovarian stimulation and oocyte retrieval on reproductive outcome in oocyte donors. | 31.7 | 0 | 2 |
| Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure | 31.7 | 0 | 2 |
| A prospective, comparative analysis of anti-Müllerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation | 31.7 | 0 | 2 |
| Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin | 31.7 | 0 | 2 |
| Ovarian stimulation, egg aspiration, in vitro fertilization and embryo transfer in the baboon (Papio anubis): a pilot project at the Institute of Primate Research, Nairobi, Kenya | 31.7 | 0 | 2 |
| Random start ovarian stimulation for fertility preservation appears unlikely to delay initiation of neoadjuvant chemotherapy for breast cancer | 31.7 | 0 | 2 |
| Need for Comprehensive Counseling in Women Requesting Oocyte Cryopreservation | 31.7 | 0 | 2 |
| Sibling embryo blastocyst development as a prognostic factor for the outcome of day-3 embryo transfer | 31.7 | 0 | 2 |
| Ovarian stimulation for fertility preservation in patients with cancer | 31.7 | 0 | 2 |
| Effective method for emergency fertility preservation: random-start controlled ovarian stimulation | 31.7 | 0 | 2 |
| Further evidence on the safety and success of ovarian stimulation with letrozole and tamoxifen in breast cancer patients undergoing in vitro fertilization to cryopreserve their embryos for fertility preservation | 31.7 | 0 | 2 |
| Evolution of a reproductive endocrinologist: the Society for Reproductive Endocrinology and Infertility fellows retreat and preliminary results of manpower survey | 31.7 | 0 | 2 |
| Serum level of anti-mullerian hormone in early follicular phase as a predictor of ovarian reserve and pregnancy outcome in assisted reproductive technology cycles | 31.7 | 0 | 2 |
| Posthumous assisted reproduction: a survey of attitudes of couples seeking fertility treatment and the degree of agreement between intimate partners | 31.7 | 0 | 2 |
| Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study | 31.7 | 0 | 2 |
| Viral infections among couples for assisted reproduction in a fertility clinic in Nigeria. | 31.7 | 0 | 2 |
| Freezing within 2 h from oocyte retrieval increases the efficiency of human oocyte cryopreservation when using a slow freezing/rapid thawing protocol with high sucrose concentration | 31.7 | 0 | 2 |
| Erratum to: Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy | 31.7 | 0 | 2 |
| Factors associated with dizygotic twinning after IVF treatment with double embryo transfer | 31.7 | 0 | 2 |
| Can highly sensitive antimüllerian hormone testing predict failed response to ovarian stimulation? | 31.7 | 0 | 2 |
| Antral follicle count, anti-mullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? | 31.7 | 0 | 2 |
| Effect of ultrasound-guided aspiration of hydrosalpingeal fluid during oocyte retrieval on the outcomes of in vitro fertilisation-embryo transfer: a randomised controlled trial (NCT01040351). | 31.7 | 0 | 2 |
| Idiopathic premature ovarian failure: what is the most suitable ovarian stimulation protocol? | 31.7 | 0 | 2 |
| The significance of antral follicle count in controlled ovarian stimulation and intrauterine insemination | 31.7 | 0 | 2 |
| Fertility preservation with ovarian stimulation protocols prior to cancer treatment | 31.7 | 0 | 2 |
| Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome | 31.7 | 0 | 2 |
| Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion | 31.7 | 0 | 2 |
| Analyzing the risk factors for a diminished oocyte retrieval rate under controlled ovarian stimulation | 31.7 | 0 | 2 |
| Age-related nomograms for antral follicle count and anti-Mullerian hormone for subfertile Chinese women in Singapore | 31.7 | 0 | 2 |
| Relationship between follicular volume and oocyte competence, blastocyst development and live-birth rate: optimal follicle size for oocyte retrieval. | 31.7 | 0 | 2 |
| Medical egg freezing: the importance of a patient-centered approach to fertility preservation | 31.7 | 0 | 2 |
| Medical egg freezing and cancer patients' hopes: Fertility preservation at the intersection of life and death | 31.7 | 0 | 2 |
| Oocyte Cryopreservation for Fertility Preservation in Healthy Women | 31.7 | 0 | 2 |
| Endometrial evaluation by aspiration biopsy on the day of oocyte retrieval in the embryo transfer cycles in patients with serum progesterone rise during the follicular phase | 31.7 | 0 | 2 |
| Diminished ovarian reserve as measured by means of baseline follicle-stimulating hormone and antral follicle count is not associated with pregnancy loss in younger in vitro fertilization patients | 31.7 | 0 | 2 |
| Knowledge, attitudes, and intentions toward fertility awareness and oocyte cryopreservation among obstetrics and gynecology resident physicians | 31.7 | 0 | 2 |
| Detectable levels of interleukin-18 in uterine luminal secretions at oocyte retrieval predict failure of the embryo transfer | 31.7 | 0 | 2 |
| Fertility preservation with ovarian stimulation and time to treatment in women with stage II-III breast cancer receiving neoadjuvant therapy | 31.7 | 0 | 2 |
| Ovarian response to controlled ovarian stimulation for fertility preservation before oncology treatment: A retrospective cohort of 157 patients | 31.7 | 0 | 2 |
| Does ovarian stimulation regimen affect IVF outcome? a two-centre, real-world retrospective study using predominantly cleavage-stage, single embryo transfer | 31.7 | 0 | 2 |
| The Impact of a Long-Acting Oral Sphingosine-1-Phosphate Analogue on Ovarian Aging in a Rat Model | 31.7 | 0 | 2 |
| Oncofertility for Adolescents: When Parents and Physicians Disagree about Egg Cryopreservation for a Mature Minor | 31.7 | 0 | 2 |
| Effects of transcutaneous electrical acupoint stimulation on ovarian reserve of patients with diminished ovarian reserve in in vitro fertilization and embryo transfer cycles | 31.7 | 0 | 2 |
| The Importance of the Periconception Period: Immediate Effects in Cattle Breeding and in Assisted Reproduction Such as Artificial Insemination and Embryo Transfer | 31.7 | 0 | 2 |
| Let us talk about eggs! Professional resistance to elective egg vitrification and gendered medical paternalism | 31.7 | 0 | 2 |
| Provision of fertility services for women at increased risk of complications during fertility treatment or pregnancy: an Ethics Committee opinion | 31.7 | 0 | 2 |
| Financial "risk-sharing" or refund programs in assisted reproduction: an Ethics Committee opinion | 31.7 | 0 | 2 |
| The impact of the new Turkish regulation, imposing single embryo transfer after assisted reproduction technology, on neonatal intensive care unit utilization: a single center experience. | 31.7 | 0 | 2 |
| Higher rates of aneuploidy in blastocysts and higher risk of no embryo transfer in recurrent pregnancy loss patients with diminished ovarian reserve undergoing in vitro fertilization | 31.7 | 0 | 2 |
| Successful controlled ovarian stimulation despite elevated hCG levels after first-trimester abortion in the context of fertility preservation | 31.7 | 0 | 2 |
| Double ovarian stimulation (DuoStim) protocol for fertility preservation in female oncology patients | 31.7 | 0 | 2 |
| Effect of different egg storage periods on some egg quality characteristics and hatchability of partridges (Alectoris graeca). | 31.7 | 0 | 2 |
| Hyperandrogenemia and ovarian reserve in patients with Mayer-Rokitansky-Küster-Hauser syndrome type 1 and 2: potential influences on ovarian stimulation. | 31.7 | 0 | 2 |
| The impact of ovarian stimulation protocol on oocyte quality, subsequent in vitro embryo development, and pregnancy after transfer to recipients in Eld's deer (Rucervus eldii thamin). | 31.7 | 0 | 2 |
| Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation. | 31.7 | 0 | 2 |
| Reproductive Ethics in Commercial Surrogacy: Decision-Making in IVF Clinics in New Delhi, India | 31.7 | 0 | 2 |
| Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes | 31.7 | 0 | 2 |
| The impact of unilateral oophorectomy on ovarian reserve in assisted reproduction: a systematic review and meta-analysis | 31.7 | 0 | 2 |
| The use of luteal-phase ovarian stimulation for poor ovarian responders undergoing in vitro fertilization/intracytoplasmic sperm injection-embryo transfer treatment | 31.7 | 0 | 2 |
| Ultrasound-guided laparotomic oocyte retrieval during surgery for fertility preservation in a case of tumor recurrence after a unilateral salpingo-oophorectomy | 31.7 | 0 | 2 |
| Assessment of ovarian reserve by antral follicle count in ovaries with endometrioma | 31.7 | 0 | 2 |
| Long-acting recombinant follicle-stimulating hormone in random-start ovarian stimulation protocols for fertility preservation in women with cancer | 31.7 | 0 | 2 |
| A specific controlled ovarian stimulation (COS) protocol for fertility preservation in women with breast cancer undergoing neoadjuvant chemotherapy | 31.7 | 0 | 2 |
| Ovulation induction and oocyte retrieval for fertility preservation in young adolescents newly diagnosed with medulloblastoma: a case series | 31.7 | 0 | 2 |
| Predictive value of antral follicle count and serum anti-Müllerian hormone: Which is better for live birth prediction in patients aged over 40 with their first IVF treatment? | 31.7 | 0 | 2 |
| New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles | 31.7 | 0 | 2 |
| Do endometriomas grow during ovarian stimulation for assisted reproduction? A three-dimensional volume analysis before and after ovarian stimulation | 31.7 | 0 | 2 |
| Medical and elective fertility preservation: impact of removal of the experimental label from oocyte cryopreservation | 31.7 | 0 | 2 |
| Impact of vitamin D levels on ovarian reserve and ovarian response to ovarian stimulation in oocyte donors | 31.7 | 0 | 2 |
| Prediction value of anti-Mullerian hormone (AMH) serum levels and antral follicle count (AFC) in hormonal contraceptive (HC) users and non-HC users undergoing IVF-PGD treatment | 31.7 | 0 | 2 |
| The psychological impact of mild ovarian stimulation combined with single embryo transfer compared with conventional IVF. | 31.7 | 0 | 2 |
| There is no evidence that the time from egg retrieval to embryo transfer affects live birth rates in a freeze-all strategy | 31.7 | 0 | 2 |
| The use of serum anti-Mullerian hormone (AMH) levels and antral follicle count (AFC) to predict the number of oocytes collected and availability of embryos for cryopreservation in IVF. | 31.7 | 0 | 2 |
| Association of a promoter polymorphism in FSHR with ovarian reserve and response to ovarian stimulation in women undergoing assisted reproductive treatment | 31.7 | 0 | 2 |
| Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation | 31.7 | 0 | 2 |
| Fertility Preservation Before Cancer Treatment: Options, Strategies, and Resources | 31.7 | 0 | 2 |
| Fertility Preservation Through Oocyte Cryopreservation in a Patient with Ovarian Dysgerminocarcinoma: A Case Report | 31.7 | 0 | 2 |
| BRCA mutation carriers show normal ovarian response in in vitro fertilization cycles | 31.7 | 0 | 2 |
| Live birth following in vitro maturation of oocytes retrieved from extracorporeal ovarian tissue aspiration and embryo cryopreservation for 5 years | 31.7 | 0 | 2 |
| Ovarian stimulation for oocyte cryopreservation for prevention of age-related fertility loss: one in five is a low responder | 31.7 | 0 | 2 |
| Differential expression of vascular endothelial growth factor angiogenic factors in different endometrial compartments in women who have an elevated progesterone level before oocyte retrieval, during in vitro fertilization-embryo transfer treatment | 31.7 | 0 | 2 |
| Left Out in the Cold: Arguments Against Non-Medical Oocyte Cryopreservation | 31.7 | 0 | 2 |
| Ureteric Injury During Transvaginal Ultrasound Guided Oocyte Retrieval | 31.7 | 0 | 2 |
| Does ovarian reserve predict egg quality in unstimulated therapeutic donor insemination cycles? | 31.7 | 0 | 2 |
| The dynamic changes of anti-Mullerian hormone and inhibin B during controlled ovarian hyperstimulation in decreased ovarian reserve women and the effect on clinical outcome | 31.7 | 0 | 2 |
| Live birth in a 50-year-old woman following in vitro fertilization–embryo transfer with autologous oocytes: a rare case report | 31.7 | 0 | 2 |
| Co-administration of GnRH-agonist and hCG, for final oocyte maturation (double trigger), in patients with low proportion of mature oocytes | 31.7 | 0 | 2 |
| A single nucleotide polymorphism of bone morphogenic protein-15 is not associated with ovarian reserve or response to ovarian stimulation | 31.7 | 0 | 2 |
| In Vivo Oocyte Retrieval in a Young Woman With Ovarian Cancer | 31.7 | 0 | 2 |
| Self-operated endovaginal telemonitoring versus traditional monitoring of ovarian stimulation in assisted reproduction: an RCT | 31.7 | 0 | 2 |
| Fertility preservation in a patient with benign multicystic peritoneal mesothelioma | 31.7 | 0 | 2 |
| Adding serum estradiol measurements to ultrasound monitoring does not change the yield of mature oocytes in IVF/ICSI. | 31.7 | 0 | 2 |
| An investigational ovarian stimulation protocol increased significantly the psychological burden in women with premature ovarian failure | 31.7 | 0 | 2 |
| Mild/minimal stimulation protocol for ovarian stimulation of patients at high risk of developing ovarian hyperstimulation syndrome | 31.7 | 0 | 2 |
| The impact of legally restricted embryo transfer and reimbursement policy on cumulative delivery rate after treatment with assisted reproduction technology | 31.7 | 0 | 2 |
| Evaluation of serum anti-Mullerian hormone levels to assess the ovarian reserve in women with severe endometriosis | 31.7 | 0 | 2 |
| Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles | 31.7 | 0 | 2 |
| What is the quality of information on social oocyte cryopreservation provided by websites of Society for Assisted Reproductive Technology member fertility clinics? | 31.7 | 0 | 2 |
| Dehydroepiandrosterone supplementation improves predictive markers for diminished ovarian reserve: serum AMH, inhibin B and antral follicle count | 31.7 | 0 | 2 |
| Prospective analysis of ovarian reserve markers as determinant in response to controlled ovarian stimulation in women undergoing IVF cycles in low resource setting in India | 31.7 | 0 | 2 |
| A prediction model to select PCOS patients suitable for IVM treatment based on anti-Mullerian hormone and antral follicle count. | 31.7 | 0 | 2 |
| Testing and interpreting measures of ovarian reserve: a committee opinion | 31.7 | 0 | 2 |
| Colour Doppler assessment of ascendent uterine artery perfusion in an in-vitro fertilization-embryo transfer programme after pituitary desensitization and ovarian stimulation with human recombinant follicle stimulating hormone | 31.7 | 0 | 2 |
| Fertility preservation using controlled ovarian hyperstimulation and oocyte cryopreservation in a premenarcheal female with myelodysplastic syndrome | 31.7 | 0 | 2 |
| Fertility preservation utilizing controlled ovarian hyperstimulation and oocyte cryopreservation in a premenarcheal female with myelodysplastic syndrome | 31.7 | 0 | 2 |
| Effects of cancer on ovarian response in controlled ovarian stimulation for fertility preservation | 31.7 | 0 | 2 |
| The effects of letrozole on ovarian stimulation for fertility preservation in cancer-affected women. | 31.7 | 0 | 2 |
| Ureteral injury after transvaginal ultrasound-guided oocyte retrieval: a complication of in vitro fertilization-embryo transfer that may lurk undetected in women presenting with severe ovarian hyperstimulation syndrome | 31.7 | 0 | 2 |
| Elevated body mass index is associated with lower serum anti-mullerian hormone levels in infertile women with diminished ovarian reserve but not with normal ovarian reserve | 31.7 | 0 | 2 |
| The effect of laparoscopic ovarian cystectomy versus coagulation in bilateral endometriomas on ovarian reserve as determined by antral follicle count and ovarian volume: a prospective randomized study | 31.7 | 0 | 2 |
| Depot GnRH-agonist trigger for breast-cancer patient undergoing ovarian stimulation resulted in mature oocytes for cryopreservation: a case report | 31.7 | 0 | 2 |
| Ex-vivo oocyte retrieval for fertility preservation | 31.7 | 0 | 2 |
| Improving fertility preservation in cancer: ovarian tissue cryobanking followed by ovarian stimulation can be efficiently combined. | 31.7 | 0 | 2 |
| Gene expression profile in the endometrium on the day of oocyte retrieval after ovarian stimulation with low-dose hCG in the follicular phase | 31.7 | 0 | 2 |
| G546A polymorphism of growth differentiation factor-9 contributes to the poor outcome of ovarian stimulation in women with diminished ovarian reserve. | 31.7 | 0 | 2 |
| Follicular-fluid anti-Mullerian hormone concentrations are predictive of assisted reproduction outcome in PCOS patients | 31.7 | 0 | 2 |
| Essential elements of informed consent for elective oocyte cryopreservation: a Practice Committee opinion | 31.7 | 0 | 2 |
| Immature oocyte retrieval in the luteal phase to preserve fertility in cancer patients | 31.7 | 0 | 2 |
| Intermittent vaginal injections of gonadotrophins for ovarian stimulation in IVF treatment | 31.7 | 0 | 2 |
| Predictors of ongoing pregnancy after single-embryo transfer following mild ovarian stimulation for IVF. | 31.7 | 0 | 2 |
| Does 3D ultrasound offer any advantage in the pretreatment assessment of ovarian reserve and prediction of outcome after assisted reproduction treatment? | 31.7 | 0 | 2 |
| Oocyte cryopreservation as alternative to embryo cryopreservation - some pertinent ethical concerns | 31.7 | 0 | 2 |
| Similar outcome for cryopreserved embryo transfer following GnRH-antagonist/GnRH-agonist, GnRH-antagonist/HCG or long protocol ovarian stimulation | 31.7 | 0 | 2 |
| Prediction of ovarian reserve based on day-3 serum follicle stimulating hormone concentrations during the pituitary suppression cycle using a gonadotropin releasing hormone agonist in patients undergoing in vitro fertilization-embryo transfer | 31.7 | 0 | 2 |
| Blastocyst development and pregnancies after IVF of mature oocytes retrieved from unstimulated patients with PCOS after in-vivo HCG priming: Case report | 31.7 | 0 | 2 |
| Assisted reproduction technique outcomes for fresh versus deferred cryopreserved day-2 embryo transfer: a retrospective matched cohort study | 31.7 | 0 | 2 |
| Massive retroperitoneal bleeding: a complication of transvaginal ultrasonography-guided oocyte retrieval for in vitro fertilization-embryo transfer | 31.7 | 0 | 2 |
| Ovarian stimulation during assisted reproduction treatment: a comparison of recombinant and highly purified urinary human FSH. On behalf of The Feronia and Apis study group | 31.7 | 0 | 2 |
| Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study | 31.7 | 0 | 2 |
| Embryo cryopreservation at the pronuclear stage and efficient embryo use optimizes the chance for a liveborn infant from a single oocyte retrieval | 31.7 | 0 | 2 |
| Limited ovarian stimulation results in the recovery of mature oocytes in polycystic ovarian disease patients: a preliminary report | 31.7 | 0 | 2 |
| Improved clinical outcomes for in vitro fertilization with delay of embryo transfer from 48 to 72 hours after oocyte retrieval: use of glucose- and phosphate-free media | 31.7 | 0 | 2 |
| Avoidance of oocyte retrieval on the weekend through the use of scheduled ovarian hyperstimulation for in vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Ovarian stimulation in women undergoing in-vitro fertilization and embryo transfer using recombinant human follicle stimulating hormone (Gonal-F) in non-down-regulated cycles | 31.7 | 0 | 2 |
| High rates of perforation are found in endovaginal ultrasound probe covers before and after oocyte retrieval for in vitro fertilization-embryo transfer | 31.7 | 0 | 2 |
| Severe ovarian hyperstimulation despite prophylactic albumin at the time of oocyte retrieval for in vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Polycystic ovary syndrome patients as oocyte donors: the effect of ovarian stimulation protocol on the implantation rate of the recipient | 31.7 | 0 | 2 |
| Endocrinology: Endogenous plasma growth hormone and the occurrence of pregnancies in patients undergoing in-vitro fertilization and embryo transfer with ovarian stimulation | 31.7 | 0 | 2 |
| Comparison of pulsatility indices on the day of oocyte retrieval and embryo transfer | 31.7 | 0 | 2 |
| Bilateral salpingectomy does not compromise ovarian stimulation in an in-vitro fertilization/embryo transfer programme | 31.7 | 0 | 2 |
| A novel ovarian stimulation protocol for use with the assisted reproductive technologies | 31.7 | 0 | 2 |
| Growth hormone, oestradiol, progesterone and testosterone concentrations in follicular fluid after ovarian stimulation with various regimes for assisted reproduction | 31.7 | 0 | 2 |
| Birthweight of singletons after assisted reproduction is higher after single- than after double-embryo transfer | 31.7 | 0 | 2 |
| Relationship between serum anti-Mullerian hormone and intrafollicular AMH levels in PCOS women | 31.7 | 0 | 2 |
| Successful Ovarian Stimulation for Fertility Preservation in a Patient with Chronic Myeloid Leukemia: Switch from Nilotinib to Interferon-α. | 31.7 | 0 | 2 |
| Oocyte vitrification versus ovarian cortex transplantation in fertility preservation for adult women undergoing gonadotoxic treatments: a prospective cohort study | 31.7 | 0 | 2 |
| Single embryo implantation per IVF cycle: the answer to every request for assisted reproduction? | 31.7 | 0 | 2 |
| Role of FSHR rs6165 and ESR2 rs4986938 polymorphisms in ovarian stimulation of Iranian women who underwent assisted reproduction treatment | 31.7 | 0 | 2 |
| Effects of embryo cryopreservation and thawing on clinical outcomes of transplantable embryos after cleavage-stage preimplantation genetic diagnosis or screening | 31.7 | 0 | 2 |
| Comparison of embryo transfer strategies and assisted reproduction outcome in Slovenian and cross-border patients | 31.7 | 0 | 2 |
| CLINICAL ASSISTED REPRODUCTION: Comparison of Recombinant and Urinary Follicle-Stimulating Hormone Preparations in Short-Term Gonadotropin Releasing Hormone Agonist Protocol for In Vitro Fertilization-Embryo Transfer | 31.7 | 0 | 2 |
| Outcome of Oocyte Vitrification Combined with Microdissection Testicular Sperm Extraction and Aspiration for Assisted Reproduction in Men. | 31.7 | 0 | 2 |
| Costs of medically assisted reproduction treatment at specialized fertility clinics in the Danish public health care system: results from a 5-year follow-up cohort study | 31.7 | 0 | 2 |
| Comparative protein expression profiling in human cumulus cells in relation to oocyte fertilization and ovarian stimulation protocol | 31.7 | 0 | 2 |
| Contribution of embryo cryopreservation to elective single embryo transfer in IVF-ICSI. | 31.7 | 0 | 2 |
| Poor oocyte retrieval is a manifestation of low ovarian reserve | 31.7 | 0 | 2 |
| Use of serum inhibin B levels at the start of ovarian stimulation and at oocyte pickup in the prediction of assisted reproduction treatment outcome | 31.7 | 0 | 2 |
| Use of fetal oocytes in assisted reproduction | 31.7 | 0 | 2 |
| What is the most relevant standard of success in assisted reproduction?: The value of cryopreservation on cumulative pregnancy rates per single oocyte retrieval should not be forgotten | 31.7 | 0 | 2 |
| Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix (Cetrotide) in controlled ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| Cetrotide confirmatory trial of cetrorelix/0.25 mg in 26 women undergoing ovarian stimulation with recombinant follicle stimulating hormones for IVF, ICSI and embryo transfer (ET). | 31.7 | 0 | 2 |
| Factors affecting the success of human blastocyst development and pregnancy following in vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Perforated appendicitis following transvaginal oocyte retrieval for in-vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Changes induced in serum protein profiles by ovarian stimulation during in-vitro fertilization--embryo transfer treatment: a comparison between conception and non-conception cycles | 31.7 | 0 | 2 |
| Further observations on serial serum immunoreactive inhibin levels in the luteal phase and early gestation after ovarian stimulation for in vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Comparison of four different ovarian stimulation protocols in an in vitro fertilisation & embryo transfer programme | 31.7 | 0 | 2 |
| Optimizing natural fertility: a committee opinion | 31.7 | 0 | 2 |
| Maternal menopause as a predictor of anti-Mullerian hormone level and antral follicle count in daughters during reproductive age. | 31.7 | 0 | 2 |
| Expectations for success in fertility treatment involving assisted reproduction | 31.7 | 0 | 2 |
| Reproductive medicine in transition: new developments in embryo transfer | 31.7 | 0 | 2 |
| Efficacy of intrauterine inseminations as a training modality for performing embryo transfer in reproductive endocrinology and infertility fellowship programs. | 31.7 | 0 | 2 |
| Annual report of Reproductive Endocrinology Committee, Japan Society of Obstetrics and Gynecology, 2013 | 31.7 | 0 | 2 |
| Clinical experience with an ovarian stimulation protocol for intrauterine insemination adopting a gonadotropin releasing hormone antagonist at low dose. | 31.7 | 0 | 2 |
| Evaluation of Ovarian Reserve Based on Hormonal Parameters, Ovarian Volume, and Antral Follicle Count in Women with Type 2 Diabetes Mellitus | 31.7 | 0 | 2 |
| Choosing the right stimulation protocol for in vitro fertilization-embryo transfer in poor, normal, and hyper-responders | 31.7 | 0 | 2 |
| With low ovarian reserve, Highly Individualized Egg Retrieval (HIER) improves IVF results by avoiding premature luteinization | 31.7 | 0 | 2 |
| Is there a need for recombinant human luteinizing hormone (lutropin alfa) supplementation in ovarian stimulation for assisted reproduction? | 31.7 | 0 | 2 |
| Predictive factors and a corresponding treatment algorithm for controlled ovarian stimulation in patients treated with recombinant human follicle stimulating hormone (follitropin alfa) during assisted reproduction technology (ART) procedures. An ana | 31.7 | 0 | 2 |
| AIDA for reproductive medicine and the fertility clinic | 31.7 | 0 | 2 |
| Selective early elimination of luteal support in assisted reproduction cycles using a gonadotropin-releasing hormone agonist during ovarian stimulation | 31.7 | 0 | 2 |
| Factors influencing the success rate of human embryo freezing in an in vitro fertilization and embryo transfer program. | 31.7 | 0 | 2 |
| Pregnancy outcomes of PCOS overweight/obese patients after controlled ovarian stimulation with the GnRH antagonist protocol and frozen embryo transfer | 31.7 | 0 | 2 |
| Beyond the American Society for Reproductive Medicine transfer guidelines: how many cleavage-stage embryos are safe to transfer in women ≥43 years old? | 31.7 | 0 | 2 |
| Estimation of ovarian response using multiple predictors of ovarian reserve in women undergoing in vitro fertilization-embryo transfer | 31.7 | 0 | 2 |
| AIUM practice guideline for ultrasonography in reproductive medicine | 31.7 | 0 | 2 |
| Clinical effects of oocyte cryopreservation in assisted reproduction technology | 31.7 | 0 | 2 |
| How to improve ART results? Is France behind other countries? Strategy for single embryo transfer: The value of embryo selection and embryo freezing | 31.7 | 0 | 2 |
| Ovarian reserve evaluation by anti-mullerian hormone in women undergoing laparoscopic cystectomy of endometrioma | 31.7 | 0 | 2 |
| Suitable fresh embryo transfer strategy for mild ovarian stimulation with clomiphene citrate | 31.7 | 0 | 2 |
| Effects of cystectomy for ovary benign cyst on ovarian reserve and pregnancy outcome of in vitro fertilization-embryo transfer cycle | 31.7 | 0 | 2 |
| Does the presence of endometriosis cause a challenge for transvaginal oocyte retrieval procedure? A comparison between patients with endometriosis and without endometriosis | 31.7 | 0 | 2 |
| In-vitro fertilization, embryo transfer, and embryo freezing | 31.7 | 0 | 2 |
| A programmed schedule of oocyte retrieval using mild ovarian stimulation (clomiphene citrate and recombinant follicle-stimulating hormone). | 31.7 | 0 | 2 |
| Luteal Phase Ovarian Stimulation May Improve Oocyte Retrieval and Oocyte Quality in Poor Ovarian Responders Undergoing In Vitro Fertilization: Preliminary Results from a Single-Center Prospective Pilot Study | 31.7 | 0 | 2 |
| Ovarian reserve and response to stimulation in women undergoing fertility preservation according to malignancy type | 31.7 | 0 | 2 |
| Ultrasound-guided Retrieval of Mature Oocytes for Fertility Preservation During Laparoscopic Oophorectomy: A Case Report | 31.7 | 0 | 2 |
| Prospective assessment of follicular growth and the oocyte cohort after ovarian stimulation for fertility preservation in 90 cancer patients versus 180 matched controls | 31.7 | 0 | 2 |
| Update on fertility preservation from the Barcelona International Society for Fertility Preservation–ESHRE–ASRM 2015 expert meeting: indications, results and future perspectives†‡ | 31.7 | 0 | 2 |
| Systematic proposal of fertility preservation by mature oocyte cryopreservation for recurrent benign ovarian tumors | 31.7 | 0 | 2 |
| Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion | 31.7 | 0 | 2 |
| Multicenter evaluation of the Access AMH antimüllerian hormone assay for the prediction of antral follicle count and poor ovarian response to controlled ovarian stimulation | 31.7 | 0 | 2 |
| In-vitro fertilization (IVF), embryo transfer (ET) and assisted reproduction in the State of Israel | 31.7 | 0 | 2 |
| The use of anti-Müllerian hormone for controlled ovarian stimulation in assisted reproductive technology, fertility assessment and -counseling | 31.7 | 0 | 2 |
| Reply: Low as well as high serum P4 levels in the early and mid-luteal phase reduce the chance of a live birth following IVF treatment with fresh embryo transfer | 31.7 | 0 | 2 |
| Low as well as high serum P4 levels in the early and mid-luteal phase reduce the chance of a live birth following IVF treatment with fresh embryo transfer: where is the evidence? | 31.7 | 0 | 2 |
| Abstracts for 2018 Foundation for Reproductive Medicine Translational Reproductive Biology and Clinical Reproductive Endocrinology Conference | 31.7 | 0 | 2 |
| Egg Quality and Pregnancy Outcome in Young Infertile Women with Diminished Ovarian Reserve | 31.7 | 0 | 2 |
| Pain relief for women undergoing oocyte retrieval for assisted reproduction | 31.7 | 0 | 2 |
| Is it safe to perform a controlled ovarian stimulation for assisted reproduction in young breast cancer survivors? | 31.7 | 0 | 2 |
| Planned oocyte cryopreservation for women seeking to preserve future reproductive potential: an Ethics Committee opinion | 31.7 | 0 | 2 |
| Misconduct in third-party assisted reproduction: an Ethics Committee opinion | 31.7 | 0 | 2 |
| Ethical obligations in fertility treatment when intimate partners withhold information from each other: an Ethics Committee opinion | 31.7 | 0 | 2 |
| Gender reassignment and assisted reproduction: An ethical analysis. Bristol Centre for Reproductive Medicine Ethics Advisory Committee | 31.7 | 0 | 2 |
| Shared-risk or refund programs in assisted reproduction. The Ethics Committee of the American Society for Reproductive Medicine | 31.7 | 0 | 2 |
| DHEA use to improve likelihood of IVF/ICSI success in patients with diminished ovarian reserve: A systematic review and meta-analysis | 31.7 | 0 | 2 |
| Blastocyst development after assisted reproduction using spermatozoa obtained after testicular stem cell transplantation in mice | 31.7 | 0 | 2 |
| Is tissue factor pathway inhibitor a marker of procoagulable status in healthy infertile women undergoing ovarian stimulation for assisted reproduction? | 31.7 | 0 | 2 |
| The effectiveness of sublingual progesterone administration during cryopreserved embryo transfer cycles: results of a matched follow-up study**Presented in part at the 51st Annual Meeting of the American Society for Reproductive Medicine, Seattle, Wa | 31.7 | 0 | 2 |
| Specific protocols of controlled ovarian stimulation for oocyte cryopreservation in breast cancer patients | 31.7 | 0 | 2 |
| Controlled ovarian stimulation protocols for assisted reproduction: a network meta-analysis | 31.7 | 0 | 2 |
| Egg freezing for fertility preservation and family planning: a nationwide survey of US Obstetrics and Gynecology residents | 31.7 | 0 | 2 |
| Bladder hematoma: a complication from an oocyte retrieval procedure | 31.7 | 0 | 2 |
| La cryopréservation ovocytaire va-t-elle relancer l’intérêt du prélèvement chirurgical de spermatozoïdes synchrone du recueil ovocytaire en cas d’azoospermie non obstructive ? | 31.7 | 0 | 2 |
| Are we choosing the correct FSH starting dose during controlled ovarian stimulation for intrauterine insemination cycles? Potential application of a nomogram based on woman’s age and markers of ovarian reserve | 31.7 | 0 | 2 |
| Fertility preservation in women with malignancies: the accuracy of antral follicle count collected randomly during the menstrual cycle in predicting the number of oocytes retrieved | 31.7 | 0 | 2 |
| Limited importance of pre-embryo pronuclear morphology (zygote score) in assisted reproduction outcome in the absence of embryo cryopreservation | 31.7 | 0 | 2 |
| Comparison of 2 Ovarian Stimulation Protocols for Women With Low Ovarian Reserve | 31.7 | 0 | 2 |
| Study to Evaluate if the Addition of r-hLH (Luveris®) to FSH From Day 8 of Ovarian Stimulation is Able to Decrease Total FSH Dose and to Improve Cycle Outcome in Infertile Women Undergoing ART, Who Required High FSH Dose in a Previous Cycle | 31.7 | 0 | 2 |
| Single Human Embryo Transfer in Assisted Reproduction Programs | 31.7 | 0 | 2 |
| Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients | 31.7 | 0 | 2 |
| Comparison of the Live Birth Rate Between the PPOS and the GnRH Antagonist Protocol in Patients Undergoing IVF | 31.7 | 0 | 2 |
| Evaluation of the Second Follicular Wave Phenomenon in Natural Cycle Assisted Reproduction: A Key Option for Poor Responders through Luteal Phase Oocyte Retrieval | 31.7 | 0 | 2 |
| Can anti-Mullerian hormone (AMH) predict the outcome of intrauterine insemination with controlled ovarian stimulation? | 31.7 | 0 | 2 |
| Clinical Cohort Study on the Endocrinology and Vaginal Microbiome of the Luteal Phase in Assisted Reproduction | 31.7 | 0 | 2 |
| Comparing Ovarian Stimulation for Assisted Reproduction With Two Different Forms of Pituitary Suppression | 31.7 | 0 | 2 |
| Effect of Oocyte Vitrification on Fertilization Rate, Embryo Quality and Development | 31.7 | 0 | 2 |
| Study to Examine Effect of Recombinant Luteinizing Hormone (r-Lh) and Recombinant Human Chorionic Gonadotropin (r-hCG) for Ovarian Stimulation in Assisted Reproduction Techniques (ART) | 31.7 | 0 | 2 |
| Oocyte Cryopreservation | 31.7 | 0 | 2 |
| Anti-mullerian Hormone (AMH) After Treatment of Endometriomas With Alcohol Sclerotherapy Versus Surgery: Clinical Trial | 31.7 | 0 | 2 |
| Interest of Automated Oocyte Freezing | 31.7 | 0 | 2 |
| Does Letrozole Improve Pregnancy Outcome in Fresh Embryo Transfer IVF/ICSI Cycle? | 31.7 | 0 | 2 |
| Comparison of Blood Flow in the Arteriae Uterinae in Ovarian Stimulation Cycles | 31.7 | 0 | 2 |
| Anti-Mullerian Hormone (AMH) is a Marker for Ovarian Reserve. There Are Many Studies About AMH Changes in Ovarian Surgery, But Little is Known for Other Surgeries. We Seek to Investigate the Hormone Variations Before and After Uterine Artey Liga | 31.7 | 0 | 2 |
| LANDA Embryo Freezing Technique. | 31.7 | 0 | 2 |
| Ovarian Stimulation: Inositol and Melatonin | 31.7 | 0 | 2 |
| A Novel Stimulation Protocol and the Conventional Low Dose Step-up and Step Down Regimens | 31.7 | 0 | 2 |
| A Randomised, Phase II, Comparative Study With a Parallel Control for Evaluating the Efficacy and Safety of Combined Treatment of Lutropin Alpha and Recombinant Human Luteinizing Hormone in the Middle of the Controlled Ovarian Stimulation Follic | 31.7 | 0 | 2 |
| Abstracts for 2017 Foundation for Reproductive Medicine Translational Reproductive Biology and Clinical Reproductive Endocrinology Conference | 31.7 | 0 | 2 |
| Neonatal outcomes following different ovarian stimulation protocols in fresh single embryo transfer | 31.7 | 0 | 2 |
| What advice should we give our patients to preserve their fertility and avoid needing oocyte donation in the future? - A Social Fertility Preservation program | 31.7 | 0 | 2 |
| Safety data for the use of nasal human menopausal gonadotropins: a potential novel approach for fertility treatment | 31.7 | 0 | 2 |
| The impact of repetitive oocyte retrieval on the ovarian reserve: a retrospective cohort study | 31.7 | 0 | 2 |
| Elective single embryo transfer in women less than age 38 years reduces multiple birth rates, but not live birth rates, in United States fertility clinics | 31.7 | 0 | 2 |
| Double Pick up in Poor Prognosis Women | 31.7 | 0 | 2 |
| Comparison of the Number of Oocytes Obtained Between Chinese and Caucasian Women in IVF Treatment | 31.7 | 0 | 2 |
| Diafert for Embryo Selection and Fertility Improvement (DESTINy) | 31.7 | 0 | 2 |
| Diafert® for Embryo Selection and Fertility Improvement | 31.7 | 0 | 2 |
| Diafert for Embryo Selection and Fertility Improvement | 31.7 | 0 | 2 |
| Administration of DHEA in Patients With Poor Response to Ovarian Stimulation for IVF | 31.7 | 0 | 2 |
| Random-start ovarian stimulation with aromatase inhibitor for fertility preservation in women with Japanese breast cancer | 31.7 | 0 | 2 |
| Correlation between Ovarian Reserve and Incidence of Ectopic Pregnancy after Fertilization and Embryo Transfer | 31.7 | 0 | 2 |
| IVF Hyper-responders: Oocyte Vitrification Compared With Embryo Freezing | 31.7 | 0 | 2 |
| Oocyte Cryopreservation Study (Egg Banking) | 31.7 | 0 | 2 |
| Biomarkers of Ovarian Reserve and Correlation With IVF Treatments | 31.7 | 0 | 2 |
| Levels of Anti-Mullerian Hormone (AMH) During Ovarian Stimulation With Gonadotropins | 31.7 | 0 | 2 |
| Clomiphene Citrate in Combination With Gonadotropins for Ovarian Stimulation in Women With Poor Ovarian Response. | 31.7 | 0 | 2 |
| A Phase III Study of FE 999913 in Japanese Female Patients Undergoing Fertility Treatment | 31.7 | 0 | 2 |
| The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol | 31.7 | 0 | 2 |
| Bed Rest or no Bed Rest? | 31.7 | 0 | 2 |
| MENOPUR in Gonadotrophin-releasing Hormone (GnRH) Antagonist Cycles With Single Embryo Transfer | 31.7 | 0 | 2 |
| Temporally Splitting Ovarian Stimulation and Embryo Transfer | 31.7 | 0 | 2 |
| Efficacy of Ovarian Stimulation Based on FSHR Genotype Status | 31.7 | 0 | 2 |
| Day of Embryo Transfer for Patients Undergoing In Vitro Fertilization | 31.7 | 0 | 2 |
| Fertility Preservation by Ovarian and Oocyte Cryopreservation | 31.7 | 0 | 2 |
| EmbryoGlue as an Embryo Transfer Medium | 31.7 | 0 | 2 |
| The Accuracy of Endometrial Ultrasound to Predict Implantation | 31.7 | 0 | 2 |
| Influence of Post-thaw Embryo Culture Interval on Assisted Reproduction Success Rates | 31.7 | 0 | 2 |
| Anti-müllerian Hormone for the Prediction of Ovarian Response in Progestin-Primed Ovarian Stimulation Protocol for IVF. | 31.7 | 0 | 2 |
| Clinical outcomes following long GnRHa ovarian stimulation with highly purified human menopausal gonadotropin plus rFSH or rFSH in patients undergoing in vitro fertilization-embryo transfer: a multi-center randomized controlled trial. | 31.7 | 0 | 2 |
| The Application of a New Ovarian Stimulation Protocol in IVF | 31.7 | 0 | 2 |
| HRT Versus MOS for Endometrial Preparation Prior to FET in PCOS Patients | 31.7 | 0 | 2 |
| Anti-Mullerian Hormone (AMH) as Marker of Ovarian Reserve | 31.7 | 0 | 2 |
| Preimplantation Genetic Diagnosis (PGD) With Gonadotropin-releasing Hormone (GnRH) Agonist Versus Antagonist | 31.7 | 0 | 2 |
| Individualization of Ovarian Stimulation Using AMH Maximizes the Benefits and Minimizes Complications and Risks | 31.7 | 0 | 2 |
| Live Birth After Fresh Embryo Transfer Vs Frozen-thawed Embryo Transfer in Women With Polycystic Ovary Syndrome | 31.7 | 0 | 2 |
| Effect of Follicular Phase Acupuncture on Anti-Mullerian Hormone in Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF And The Effect on Assisted Reproduction Outcome | 31.7 | 0 | 2 |
| Antimullerian Hormone in Endometriomas | 31.7 | 0 | 2 |
| Fertility Preservation in Breast Cancer Patients | 31.7 | 0 | 2 |
| The Affect of Hemostasis Technique During Laparoscopic Ovarian Cystectomy on Future Fertility | 31.7 | 0 | 2 |
| NATural Ovarian Stimulation | 31.7 | 0 | 2 |
| Evaluating the AMH Levels During Natural Cycle | 31.7 | 0 | 2 |
| Predictors of Postoperative Pain Following Oocyte Retrieval for Assisted Reproduction | 31.7 | 0 | 2 |
| Mapping the Endocrine Determinants of Ovarian Stimulation to Optimize Outcomes in Fresh Embryo Transfer Cycles | 31.7 | 0 | 2 |
| Antimullerian Hormone Versus Antral Follicle Count for Determination of Gonadotrophin Dosing in IVF | 31.7 | 0 | 2 |
| Efficacy of Corifollitropin Alfa Versus Follitropin Beta in Aged IVF (In-vitro Fertilization) Patients | 31.7 | 0 | 2 |
| HRT Versus MOS for Endometrial Preparation Prior to FET in Non PCOS Patients | 31.7 | 0 | 2 |
| Ovarian stimulation protocol for in vitro fertilization with gonadotropin-releasing hormone agonist widens the implantation window | 31.7 | 0 | 2 |
| The development of an efficient ambulatory in vitro fertilization (IVF) and embryo transfer (ET) program using ultrasonically guided oocyte retrieval | 31.7 | 0 | 2 |
| Cardiomyopathy in a patient undergoing laparoscopy for oocyte retrieval during in vitro fertilization/embryo transfer. A case report | 31.7 | 0 | 2 |
| Experience with a new fixed-stimulation protocol without hormone determinations for programmed oocyte retrieval for in-vitro fertilization | 31.7 | 0 | 2 |
| Outcome of in-vitro fertilization and embryo transfer after different regimens of ovarian stimulation | 31.7 | 0 | 2 |
| Differential indications for surgical technics in reproductive medicine--microsurgery, in vitro fertilization and embryo transfer, gamete intrafallopian transfer and tubal embryo transfer | 31.7 | 0 | 2 |
| Clomiphene-HMG ovarian stimulation in human in vitro fertilization and embryo transfer | 31.7 | 0 | 2 |
| Programmed oocyte retrieval during routine laparoscopy and embryo cryopreservation for later transfer | 31.7 | 0 | 2 |
| In vitro fertilization and other assisted reproduction. Vth World Congress on In Vitro Fertilization and Embryo Transfer. Norfolk, Virginia, April 5-10, 1987. Proceedings | 31.7 | 0 | 2 |
| An analysis of the LH profile in relation to ovarian stimulation regimes and embryo transfer rates in an in vitro fertilisation programme | 31.7 | 0 | 2 |
| Choice of an ovarian stimulation protocol according to the follicular puncture method in an in vitro fertilization programme | 31.7 | 0 | 2 |
| The effect of periovarian adhesions on follicular development in patients undergoing ovarian stimulation for in vitro fertilization-embryo transfer | 31.7 | 0 | 2 |
| The functional ovarian reserve in assisted reproduction. A clinical dilemma | 31.7 | 0 | 2 |
| Sonographically monitored ovarian stimulation for assisted reproduction: a prospective, blind study | 31.7 | 0 | 2 |
| Methodology of human embryo transfer following assisted reproduction | 31.7 | 0 | 2 |
| Ovarian stimulation protocol and the outcome of in vitro fertilization are not related to the ability of follicular fluid to induce sperm acrosome reaction | 31.7 | 0 | 2 |
| Luteinizing hormone (LH) surge in patients using buserelin spray during ovarian stimulation for assisted reproduction | 31.7 | 0 | 2 |
| Reproductive medicine and assisted reproduction--present status and perspectives in the Czech Republic | 31.7 | 0 | 2 |
| Serum oestradiol and progesterone concentrations during prolonged coasting in 15 women at risk of ovarian hyperstimulation syndrome following ovarian stimulation for assisted reproduction treatment | 31.7 | 0 | 2 |
| A comparison of early gestational age markers in viable twin pregnancies resulting from in vitro fertilization-embryo transfer versus spontaneous conception with ovarian stimulation | 31.7 | 0 | 2 |
| A rational basis for antiphospholipid antibody testing and selective immunotherapy in assisted reproduction: a rebuttal to the American Society for Reproductive Medicine Practice opinion. American Society for Reproductive Immunology Antiphospholipid | 31.7 | 0 | 2 |
| Recombinant versus urinary FSH for ovarian stimulation in assisted reproduction | 31.7 | 0 | 2 |
| Embryo transfer: a critical step in assisted reproduction | 31.7 | 0 | 2 |
| A case of forearm amputation after ovarian stimulation for in vitro fertilization-embryo transfer | 31.7 | 0 | 2 |
| Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation | 31.7 | 0 | 2 |
| Transfer of early-cleaved embryos increases implantation rate in patients undergoing ovarian stimulation and ICSI-embryo transfer | 31.7 | 0 | 2 |
| Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction | 31.7 | 0 | 2 |
| Follitropin-alfa for ovarian stimulation during assisted reproduction treatment: a national collaborative study | 31.7 | 0 | 2 |
| Rate of blastocyst development from excess embryos remaining in culture after day 3 embryo transfer | 31.7 | 0 | 2 |
| Ovarian tissue and oocyte cryopreservation | 31.7 | 0 | 2 |
| Blastocyst culture and transfer in clinical-assisted reproduction | 31.7 | 0 | 2 |
| Access to fertility treatment by gays, lesbians, and unmarried persons | 31.7 | 0 | 2 |
| Assessment of United States fertility clinic websites according to the American Society for Reproductive Medicine (ASRM)/Society for Assisted Reproductive Technology (SART) guidelines | 31.7 | 0 | 2 |
| [Towards a single embryo transfer: predictive value of uterine and embryological parameters in assisted reproduction outcome] | 31.7 | 0 | 2 |
| Cervical dilatation with hygroscopic rods prior to ovarian stimulation facilitates embryo transfer | 31.7 | 0 | 2 |
| Elective single embryo transfer in assisted reproduction | 31.7 | 0 | 2 |
| Removal of cervical mucus prior to embryo transfer improves pregnancy rates in women undergoing assisted reproduction | 31.7 | 0 | 2 |
| Ovarian Reserve and Ankylosing Spondylitis | 31.7 | 0 | 2 |
| Measurement of anti-mullerian hormone by Beckman Coulter ELISA and DSL ELISA in assisted reproduction: differences between serum and follicular fluid | 31.7 | 0 | 2 |
| Blastocyst production and transfer in clinical assisted reproduction | 31.7 | 0 | 2 |
| Shared-risk or refund programs in assisted reproduction | 31.7 | 0 | 2 |
| Assisted reproduction in male cancer survivors: fertility treatment and outcome in 67 couples | 31.7 | 0 | 2 |
| Clinical outcome with half-dose depot triptorelin is the same as reduced-dose daily buserelin in a long protocol of controlled ovarian stimulation for ICSI/embryo transfer: a randomized double-blind clinical trial (NCT00461916) | 31.7 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile | 31.7 | 0 | 2 |
| Would legislation imposing single embryo transfer be a feasible way to reduce the rate of multiple pregnancies after IVF treatment? | 31.7 | 0 | 2 |
| Elective single embryo transfer versus double embryo transfer in assisted reproduction | 31.7 | 0 | 2 |
| Single embryo transfer in IVF treatment | 31.7 | 0 | 2 |
| Embryo fragmentation as a determinant of blastocyst development in vitro and pregnancy outcomes following embryo transfer | 31.7 | 0 | 2 |
| Recombinant gonadotrophins in reproductive medicine: gold standard for ovarian stimulation therapy in the 21st century | 31.7 | 0 | 2 |
| Guidelines for reducing the risk of viral transmission during fertility treatment | 31.7 | 0 | 2 |
| Ovarian tissue and oocyte cryopreservation | 31.7 | 0 | 2 |
| Antral follicle count in clinical practice: building the bridge from ovarian reserve to in vitro fertilization outcome | 31.7 | 0 | 2 |
| Effect of the new legislation and single-embryo transfer policy in Turkey on assisted reproduction outcomes: preliminary results | 31.7 | 0 | 2 |
| Effect of different egg storage times on some egg quality characteristics and hatchability of pheasants (Phasianus colchicus) | 31.7 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile: a committee opinion | 31.7 | 0 | 2 |
| Results after assisted reproduction at a public fertility clinic | 31.7 | 0 | 2 |
| Reproductive endocrinology: vitamin D and AMH levels are correlated in human adults | 31.7 | 0 | 2 |
| Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle | 31.7 | 0 | 2 |
| Female fertility preservation: feasibility of emergency IVF for embryo freezing | 31.7 | 0 | 2 |
| Strategies for hormonal ovarian stimulation in IVF, based on materials of the centre for assisted reproduction "varna" | 31.7 | 0 | 2 |
| Effect of different embryo transfer strategies on the outcome of assisted reproduction | 31.7 | 0 | 2 |
| Quantifying effect of combined oral contraceptive pill on functional ovarian reserve as measured by serum anti‐Müllerian hormone and small antral follicle count using three‐dimensional ultrasound | 31.7 | 0 | 2 |
| Uterine contractile activity at Embryo Transfer – as a new pharmacotherapeutic target in assisted reproduction | 31.7 | 0 | 2 |
| Serum anti-Mullerian hormone assessment of ovarian reserve and polycystic ovary syndrome status over the reproductive lifespan | 31.7 | 0 | 2 |
| AIUM Practice Guideline for the Performance of a Focused Reproductive Endocrinology and Infertility Scan | 31.7 | 0 | 2 |
| Reply: Endometrioma excision and ovarian reserve: do assessments by antral follicle count and anti-Müllerian hormone yield contradictory results? | 31.7 | 0 | 2 |
| Endometrioma excision and ovarian reserve; do assessments by antral follicle count and anti-Müllerian hormone yield contradictory results? | 31.7 | 0 | 2 |
| Ovarian reserve and anti-Mullerian hormone (AMH) in mothers of dizygotic twins | 31.7 | 0 | 2 |
| Comparing the Effect of Laparoscopic Supracervical and Total Hysterectomy for Uterine Fibroids on Ovarian Reserve by Assessing Serum Anti-Mullerian Hormone Levels: A Prospective Cohort Study | 31.7 | 0 | 2 |
| The effect of isotretinoin on ovarian reserve based on hormonal parameters, ovarian volume, and antral follicle count in women with acne | 31.7 | 0 | 2 |
| Freeze-all policy: fresh vs. frozen-thawed embryo transfer | 31.7 | 0 | 2 |
| Role of ovarian reserve markers, antimüllerian hormone and antral follicle count, as aneuploidy markers in ongoing pregnancies and miscarriages | 31.7 | 0 | 2 |
| Surgery Before Embryo Transfer in ERROR (Endometrioma Related Reduction in Ovarian Reserve) | 31.7 | 0 | 2 |
| Comparison between two protocols for thawed embryo transfer: natural cycle versus exogenous hormone replacement | 31.7 | 0 | 2 |
| Successful pregnancy following assisted reproduction and transmyometrial embryo transfer in a patient with anatomical distortion of the cervical canal | 31.7 | 0 | 2 |
| Follicle-Stimulating Hormone/Luteinizing Hormone Ratio as an Independent Predictor of Response to Controlled Ovarian Stimulation | 31.7 | 0 | 2 |
| The effect of premature luteinizing hormone increases among high ovarian responders undergoing a gonadotropin-releasing hormone antagonist ovarian stimulation protocol | 31.7 | 0 | 2 |
| Usefulness of individualized FSH, LH and GH dosing in ovarian stimulation of women with low ovarian reserve | 31.7 | 0 | 2 |
| Evaluation of ovarian reserve using anti-müllerian hormone and antral follicle count in Sjögren's syndrome: Preliminary study | 31.7 | 0 | 2 |
| Comparison of pregnancy rates for poor responders using IVF with mild ovarian stimulation versus conventional IVF: a guideline | 31.7 | 0 | 2 |
| ASRM standard embryo transfer protocol template: a committee opinion | 31.7 | 0 | 2 |
| The use of autologous platelet-rich plasma (PRP) versus no intervention in women with low ovarian reserve undergoing fertility treatment: a non-randomized interventional study | 31.7 | 0 | 2 |
| Compassionate transfer: patient requests for embryo transfer for nonreproductive purposes | 31.7 | 0 | 2 |
| Use of exogenous gonadotropins for ovulation induction in anovulatory women: a committee opinion | 31.7 | 0 | 2 |
| Fertility Preservation Before Deployment: Oocyte and Sperm Freezing in Members of the Active Duty Military | 31.7 | 0 | 2 |
| Timing of frozen-thawed embryo transfer after controlled ovarian stimulation in a non-elective freeze-all policy | 31.7 | 0 | 2 |
| Current Preventive Strategies for Preovulatory Progesterone Elevation During Ovarian Stimulation for In Vitro Fertilization | 31.7 | 0 | 2 |
| Outcomes of fertility preservation in women with endometriosis: comparison of progestin-primed ovarian stimulation versus antagonist protocols | 31.7 | 0 | 2 |
| Oncologic oocyte cryopreservation: national comparison of fertility preservation between women with and without cancer | 31.7 | 0 | 2 |
| Blastocyst culture and transfer in clinically assisted reproduction: a committee opinion | 31.7 | 0 | 2 |
| Ovarian stimulation for fertility preservation in women diagnosed with cancer | 31.7 | 0 | 2 |
| The impact of malignancy on response to ovarian stimulation for fertility preservation: a meta-analysis | 31.7 | 0 | 2 |
| Serum anti-Mullerian hormone (AMH) concentration has limited prognostic value for density of primordial and primary follicles, questioning it as an accurate parameter for the ovarian reserve | 31.7 | 0 | 2 |
| Outcomes of ovarian stimulation and fertility preservation in breast cancer patients with different hormonal receptor profiles | 31.7 | 0 | 2 |
| Oocyte vitrification for fertility preservation in women with endometriosis: an observational study | 31.7 | 0 | 2 |
| Outcomes of in vitro fertilization-embryo transfer in women with diminished ovarian reserve after growth hormone pretreatment | 31.7 | 0 | 2 |
| Ovarian stimulation for oocyte vitrification does not modify disease-free survival and overall survival rates in patients with early breast cancer | 31.7 | 0 | 2 |
| Elective Single Embryo Transfer in the Setting of Funded In Vitro Fertilization: Two Years' Experience in an Ontario Hospital-Based Fertility Clinic | 31.7 | 0 | 2 |
| Curative effect of assisted reproduction technology by Traditional Chinese Medicine multi-channel interventional therapy on 95 cases of in vitro fertilization and embryo transfer failure | 31.7 | 0 | 2 |
| Androgenicity and fertility treatment in women with unexplained infertility | 31.7 | 0 | 2 |
| Mild stimulation protocol vs conventional controlled ovarian stimulation protocol in poor ovarian response patients: a prospective randomized controlled trial | 31.7 | 0 | 2 |
| The effect of acupuncture on anti-mullerian hormone and assisted reproduction outcome in Polycystic Ovary Syndrome patients undergoing in vitro fertilization | 31.7 | 0 | 2 |
| Effect of Progestin-primed Ovarian Stimulation Protocol on Outcomes of Aged Infertile Women Who Failed to Get Pregnant in the First IVF/ ICSI Cycle: A Self-controlled Study | 31.7 | 0 | 2 |
| Evaluating the benefit of measuring serum progesterone prior to the administration of HCG: effect of the duration of late-follicular elevated progesterone following ovarian stimulation on fresh embryo transfer live birth rates | 31.7 | 0 | 2 |
| Vitamin D Deficiency Is Associated With Poor Ovarian Stimulation Outcome in PCOS but Not Unexplained Infertility | 31.7 | 0 | 2 |
| Outcome of ovarian stimulation for oocyte cryopreservation in women with Turner syndrome | 31.7 | 0 | 2 |
| Knowledge and decision making about future fertility and oocyte cryopreservation among young women | 31.7 | 0 | 2 |
| Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients | 31.7 | 0 | 2 |
| Oocyte exposure to supraphysiological estradiol during ovarian stimulation increased the risk of adverse perinatal outcomes after frozen-thawed embryo transfer: a retrospective cohort study | 31.7 | 0 | 2 |
| Optimal Ovulation Trigger-Oocyte Pickup Interval in Progestin-Primed Ovarian Stimulation Protocol: A Retrospective Study Using Propensity Score Matching | 31.7 | 0 | 2 |
| Egg storage and breeder age impact on egg quality and embryo development | 31.7 | 0 | 2 |
| Effects of cancer stage and grade on fertility preservation outcome and ovarian stimulation response | 31.7 | 0 | 2 |
| Dual oocyte retrieval and embryo transfer in the same cycle for women with premature ovarian insufficiency | 31.7 | 0 | 2 |
| Failed sperm retrieval from severely oligospermic or non-obstructive azoospermic patients on oocyte retrieval day: Emergent oocyte cryopreservation is a feasible strategy | 31.7 | 0 | 2 |
| Vaginal cuff dehiscence following controlled ovarian stimulation recognized during egg retrieval | 31.7 | 0 | 2 |
| Defining thresholds for abnormal premature progesterone levels during ovarian stimulation for assisted reproduction technologies | 31.7 | 0 | 2 |
| Abstracts presented at the 2019 Foundation for Reproductive Medicine Conference on Translational Reproductive Biology and Clinical Reproductive Endocrinology | 31.7 | 0 | 2 |
| The ethics of fertility treatment for same-sex male couples: Considerations for a modern fertility clinic | 31.7 | 0 | 2 |
| [Medically Assisted Reproduction in Natural Cycle: Outcome Evaluation of a Reproductive Medicine Department] | 31.7 | 0 | 2 |
| Expression of the anti-Mullerian hormone, kisspeptin 1, and kisspeptin 1 receptor in polycystic ovary syndrome and controlled ovarian stimulation rat models | 31.7 | 0 | 2 |
| Corticosteroids Prior to Embryo Transfer in Assisted Reproduction in Women with Crohn's Disease and Ulcerative Colitis - A Nationwide Cohort Study | 31.7 | 0 | 2 |
| What is the true place of a double stimulation and double oocyte retrieval in the same cycle for patients diagnosed with poor ovarian reserve? A systematic review including a meta-analytical approach | 31.7 | 0 | 2 |
| The impact of the localisation of endometriosis lesions on ovarian reserve and assisted reproduction techniques outcomes | 31.7 | 0 | 2 |
| Combination Treatment of Preoperative Embryo Cryopreservation and Endoscopic Surgery (Surgery-ART Hybrid Therapy) in Infertile Women with Diminished Ovarian Reserve and Uterine Myomas or Ovarian Endometriomas | 31.7 | 0 | 2 |
| Risk factors for inadequate response to ovarian stimulation in assisted reproduction cycles: systematic review | 31.7 | 0 | 2 |
| Hemodynamic parameters and reproductive outcome after intracytoplasmic sperm injection and fresh embryo transfer in patients undergoing oocyte retrieval with general anesthesia using fentanyl, remifentanil or alfentanil - A randomized clinical trial | 31.7 | 0 | 2 |
| Ovarian stimulation is a safe and effective fertility preservation option in the adolescent and young adult population | 31.7 | 0 | 2 |
| Oocyte cryopreservation for fertility preservation in women with ovarian endometriosis | 31.7 | 0 | 2 |
| Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion | 31.7 | 0 | 2 |
| Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study | 31.7 | 0 | 2 |
| Use of Frozen Embryo Transfer During Fertility Treatment and Risk of Childhood Cancer | 31.7 | 0 | 2 |
| Use of Frozen Embryo Transfer During Fertility Treatment and Risk of Childhood Cancer-Reply | 31.7 | 0 | 2 |
| Comparison of two different oocyte vitrification methods: a prospective, paired study on the same genetic background and stimulation protocol | 31.7 | 0 | 2 |
| Impact of BRCA1 and BRCA2 mutations on ovarian reserve and fertility preservation outcomes in young women with breast cancer | 31.7 | 0 | 2 |
| Isthmocele and ovarian stimulation for IVF: considerations for a reproductive medicine specialist | 31.7 | 0 | 2 |
| Comparison of a novel flexible progestin primed ovarian stimulation protocol and the flexible gonadotropin-releasing hormone antagonist protocol for assisted reproductive technology | 31.7 | 0 | 2 |
| Ovarian reserve parameters and response to controlled ovarian stimulation in infertile patients | 31.7 | 0 | 2 |
| Fertility treatment when the prognosis is very poor or futile: an Ethics Committee opinion | 31.7 | 0 | 2 |
| Effect of the time for embryo transfer from oocyte retrieval on clinical outcomes in freeze-all cycles: a retrospective cohort study | 31.7 | 0 | 2 |
| Minimally Invasive Embryo Transfer and Embryo Vitrification at the Optimal Embryo Stage in Rabbit Model | 31.7 | 0 | 2 |
| Use of Growth Hormone in the IVF Treatment of Women With Poor Ovarian Reserve | 31.7 | 0 | 2 |
| Exposure to Fine Particulate Matter and Ovarian Reserve Among Women from a Fertility Clinic | 31.7 | 0 | 2 |
| Ovarian stimulation and egg retrieval in the acutely ill patient: special considerations | 31.7 | 0 | 2 |
| Endometrial thickness on the day of embryo transfer is a poor predictor of IVF treatment outcome | 31.7 | 0 | 2 |
| Elective egg freezing and male support: a qualitative study of men's roles in women's fertility preservation | 31.7 | 0 | 2 |
| Analysis of embryo quality with luteal phase ovarian stimulation after failed in vitro fertilization-embryo transfer with long or ultra-long protocol | 31.7 | 0 | 2 |
| Low Dose Growth Hormone Adjuvant Treatment With Ultra-Long Ovarian Stimulation Protocol in Poor Responders Showed Non-inferior Pregnancy Outcome Compared With Normal Responders | 31.7 | 0 | 2 |
| Delayed frozen embryo transfer failed to improve live birth rate and neonatal outcomes in patients requiring whole embryo freezing | 31.7 | 0 | 2 |
| A novel de novo partial xq duplication in a girl with short stature, nonverbal learning disability and diminished ovarian reserve - effect of growth hormone treatment and fertility preservation strategies: a case report and up-to-date review | 31.7 | 0 | 2 |
| Investigating the effect of lifestyle risk factors upon number of aspirated and mature oocytes in in vitro fertilization cycles: Interaction with antral follicle count | 31.7 | 0 | 2 |
| Effect of Switching from a Progestin-Primed Ovarian Stimulation Protocol to a Modified Ultra-Long Protocol Among Women Who Had 1 Progestin-Primed Ovarian Stimulation (PPOS) Failure Verses Those Who Had 2 PPOS Failures | 31.7 | 0 | 2 |
| Ovarian stimulation for fertility preservation or family building in a cohort of transgender men | 31.7 | 0 | 2 |
| Neonatal outcomes and congenital malformations in children born after dydrogesterone application in progestin-primed ovarian stimulation protocol for IVF: a retrospective cohort study | 31.7 | 0 | 2 |
| Progestin-primed ovarian stimulation improves the outcomes of IVF/ICSI cycles in infertile women with diminished ovarian reserve | 31.7 | 0 | 2 |
| Transvaginal ovarian drilling followed by controlled ovarian stimulation from the next day improves ovarian response for the poor responders with polycystic ovary syndrome during IVF treatment: a pilot study | 31.7 | 0 | 2 |
| Evaluation of the effect of the elective blastocyst-stage embryo transfer and freezing strategy on the abandonment of frozen embryos under the Taiwan National Assisted Reproduction Act | 31.7 | 0 | 2 |
| Oocyte retrieval in an in vitro fertilization-embryo transfer program: comparison of four methods | 31.7 | 0 | 2 |
| SUN-266 Anti-Mullerian Hormone as a Marker of Ovarian Reserve in Female Pediatric Patients Undergoing Hematopoietic Stem Cell Transplantation | 31.7 | 0 | 2 |
| OR11-3 Evidence for Preserved Ovarian Reserve in Transgender Men Receiving Testosterone Therapy: Anti-Mullerian Hormone Serum Levels Decrease Modestly after One Year of Treatment | 31.7 | 0 | 2 |
| [Elective single embryo transfer in assisted reproduction] | 31.7 | 0 | 2 |
| When is the optimal timing of frozen embryo transfer after controlled ovarian stimulation? | 31.7 | 0 | 2 |
| Intraindividual Embryo Morphokinetics Are Not Affected by a Switch of the Ovarian Stimulation Protocol Between GnRH Agonist vs. Antagonist Regimens in Consecutive Cycles | 31.7 | 0 | 2 |
| Changes in the levels of selected metabolites in the culture medium as a possible tool for the embryo selection in assisted reproduction | 31.7 | 0 | 2 |
| [INFLUENCE OF STIMULATION PROTOCOL ON MATURITY AND MORPHOLOGICAL FEATURES OF OOCYTES IN PATIENTS WITH LOW OVARIAN RESERVE: STUDY OF 72 IVF/ICSI TREATMENT CYCLES] | 31.7 | 0 | 2 |
| Level of AMH as a predictor of the result of ovarian stimulation | 31.7 | 0 | 2 |
| Effect of triple line vs isoechogenic endometrial texture on pregnancy outcome following embryo transfer according to use of controlled ovarian stimulation (COH) or estrogen/progesterone replacement | 31.7 | 0 | 2 |
| Ovarian stimulation after dehydroepiandrosterone supplementation in poor ovarian reserve: a randomized clinical trial | 31.7 | 0 | 2 |
| Impact of ABVD chemotherapy on ovarian reserve after fertility preservation in reproductive-aged women with Hodgkin lymphoma | 31.7 | 0 | 2 |
| Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response | 31.7 | 0 | 2 |
| Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Patients Undergoing PGT-A | 31.7 | 0 | 2 |
| Attitudes and experiences of health care professionals when caring for transgender men undergoing fertility preservation by egg freezing: a qualitative study | 31.7 | 0 | 2 |
| Delay in IVF treatment up to 180 days does not affect pregnancy outcomes in women with diminished ovarian reserve | 31.7 | 0 | 2 |
| Delayed versus immediate frozen embryo transfer after oocyte retrieval: a systematic review and meta-analysis | 31.7 | 0 | 2 |
| Validating the Use of Corifollitropin Alfa in Progestin-Primed Ovarian Stimulation Protocol on Normal and High Responders by Comparing with Conventional Antagonist Protocol: A Retrospective Study | 31.7 | 0 | 2 |
| How fixed versus variable gonadotropin dose during controlled ovarian stimulation could influence the management of infertility patients undergoing IVF treatment: a national Delphi consensus | 31.7 | 0 | 2 |
| The PARP inhibitor, olaparib, depletes the ovarian reserve in mice: implications for fertility preservation | 31.7 | 0 | 2 |
| The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol | 31.7 | 0 | 2 |
| Aneuploid embryo transfer: clinical policies and provider opinions at United States fertility clinics | 31.7 | 0 | 2 |
| Importance of early and precise ascertainment of mosaic Turner syndrome for fertility preservation and assisted reproduction counseling | 31.7 | 0 | 2 |
| The quality of information about elective oocyte cryopreservation (EOC) on Australian fertility clinic websites | 31.7 | 0 | 2 |
| Anti-Müllerian hormone and antral follicle count differ in their ability to predict cumulative treatment outcomes of the first complete ovarian stimulation cycle in patients from POSEIDON groups 3 and 4 | 31.7 | 0 | 2 |
| Dietary patterns and ovarian reserve among women attending a fertility clinic | 31.7 | 0 | 2 |
| Is serum anti-Müllerian hormone (AMH) assay a satisfactory measure for ovarian reserve estimation? A comparison of serum and peritoneal fluid AMH levels | 31.7 | 0 | 2 |
| Differences in perceived stress during ovarian stimulation between women with infertility and those pursing oocyte cryopreservation | 31.7 | 0 | 2 |
| The indication for fertility preservation in women with Turner syndrome should not only be based on the ovarian reserve but also on the genotype and expected future health status | 31.7 | 0 | 2 |
| The comparison of evaluative effectiveness between antral follicle count/age ratio and ovarian response prediction index for the ovarian reserve and response functions in infertile women | 31.7 | 0 | 2 |
| Further evidence that a supraphysiologic estradiol level during ovarian stimulation affects birthweight: findings of fresh and frozen embryo transfer with comparable estradiol levels on human chorionic gonadotropin trigger | 31.7 | 0 | 2 |
| Endometrial thickness after ovarian stimulation with gonadotropin, clomiphene, or letrozole for unexplained infertility, and association with treatment outcomes | 31.7 | 0 | 2 |
| Interactions between Egg Storage Duration and Breeder Age on Selected Egg Quality, Hatching Results, and Chicken Quality | 31.7 | 0 | 2 |
| Early Progesterone Change Associated With Pregnancy Outcome After Fresh Embryo Transfer in Assisted Reproduction Technology Cycles With Progesterone Level of >1.5 ng/ml on Human Chorionic Gonadotropin Trigger Day | 31.7 | 0 | 2 |
| Efficacy and Safety of Controlled Ovarian Stimulation With or Without Letrozole Co-administration for Fertility Preservation: A Systematic Review and Meta-Analysis | 31.7 | 0 | 2 |
| Double-in vitro maturation increases the number of vitrified oocytes available for fertility preservation when ovarian stimulation is unfeasible | 31.7 | 0 | 2 |
| Is intrauterine insemination a viable treatment option for women over 43 years old? An analysis by ovarian stimulation protocol and sperm source | 31.7 | 0 | 2 |
| The effect of selenium and vitamin E supplementation on anti-Mullerian hormone and antral follicle count in infertile women with occult premature ovarian insufficiency: A randomized controlled clinical trial | 31.7 | 0 | 2 |
| Effect of a dual trigger on oocyte maturation in young women with decreased ovarian reserve for the purpose of elective oocyte cryopreservation | 31.7 | 0 | 2 |
| Comparison of a progestin-primed ovarian stimulation protocol with a flexible GnRH antagonist protocol in patients with polycystic ovary syndrome who are participating in an IVF programme: study protocol for a randomised controlled trial | 31.7 | 0 | 2 |
| Testing and interpreting measures of ovarian reserve: a committee opinion | 31.7 | 0 | 2 |
| Recommendations for reducing the risk of viral transmission during fertility treatment with the use of autologous gametes: a committee opinion | 31.7 | 0 | 2 |
| The marketing of elective egg freezing: A content, cost and quality analysis of UK fertility clinic websites | 31.7 | 0 | 2 |
| Simulation training for embryo transfer: findings from the American Society for Reproductive Medicine Embryo Transfer Certificate Course | 31.7 | 0 | 2 |
| EXPRESS: Porphyria Cutanea Tarda precipitated by ovarian stimulation during oocyte retrieval in a genetically susceptible female | 31.7 | 0 | 2 |
| An in silico model using prognostic genetic factors for ovarian response in controlled ovarian stimulation: A systematic review | 31.7 | 0 | 2 |
| Opioid Based Analgesia vs Non-opioid Analgesia for Oocyte Retrieval Procedure - a Randomized Clinical Trial | 31.7 | 0 | 2 |
| Planned oocyte cryopreservation for fertility preservation | 31.7 | 0 | 2 |
| A Federated Blockchain Approach for Fertility Preservation and Assisted Reproduction in Smart Cities | 31.7 | 0 | 2 |
| Fertility Preservation for Adolescent and Young Adult Transmen: A Case Series and Insights on Oocyte Cryopreservation | 31.7 | 0 | 2 |
| Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger? | 31.7 | 0 | 2 |
| Women’s preferences concerning IVF treatment: a discrete choice experiment with particular focus on embryo transfer policy | 31.7 | 0 | 2 |
| Oral Versus Intravenous Acetaminophen for Postoperative Pain Control | 31.7 | 0 | 2 |
| Analysis of the Composition of the Vaginal Microbiota During IVF Treatment and Correlation With Serum Progesterone Level on the Day of Embryo Transfer | 31.7 | 0 | 2 |
| Efficacy and Safety of Gushen Antai Pill on Ongoing Pregnancy Rate in Women With Normal Ovarian Reserve Undergoing IVF-ET | 31.7 | 0 | 2 |
| Impact of Laparoscopic Ovarian Drilling on Ovarian Reserve in Patients With Anovulatory Polycystic Ovarian Syndrome | 31.7 | 0 | 2 |
| Anti-Mullerian Hormone as a Marker of Ovarian Reserve and Function | 31.7 | 0 | 2 |
| Minimally Invasive Embryo Transfer and Embryo Vitrification at the Optimal Embryo Stage in Rabbit Model | 31.7 | 0 | 2 |
| Effect of egg storage duration and egg turning during storage on egg quality and hatching of broiler hatching eggs | 31.7 | 0 | 2 |
| Effects of controlled ovarian stimulation regimens on top-quality blastocyst development and perinatal outcomes with the freeze-all strategy: A retrospective comparative study | 31.7 | 0 | 2 |
| Surgery Before Embryo Transfer in ERROR (Endometrioma Related Reduction in Ovarian Reserve) | 31.7 | 0 | 2 |
| Pregnancy Rate (PR) With In-Vitro Fertilization (IVF) When the Egg Retrieval (ER) and the Embryo Transfer (ET) are Done by the Same Physician or by Different Physicians | 31.7 | 0 | 2 |
| Urinary Triclosan Concentrations and Diminished Ovarian Reserve among Women from a Fertility Clinic | 31.7 | 0 | 2 |
| A 5-year analysis of demographics, cycle characteristics and reproductive outcomes of 907 egg freezing cycles in patients with diminished ovarian reserve and age-related fertility decline | 31.7 | 0 | 2 |
| Physicians should avoid changing a patient’s ovarian stimulation protocol for the purpose of improving laboratory outcomes | 31.7 | 0 | 2 |
| Towards personalised reproductive medicine: screening for genetic variants and its influence in controlled ovarian stimulation | 31.7 | 0 | 2 |
| Gonadotropin-specific follicular steroidogenesis in ovarian stimulation: evidence from the menopur in GnRH antagonist single embryo transfer - high responder (MEGASET-HR) trial | 31.7 | 0 | 2 |
| Use of luteinizing hormone supplementation for ovarian stimulation in IVF/ICSI cycles of women with good ovarian reserve | 31.7 | 0 | 2 |
| A novel flexible progestin primed ovarian stimulation protocol: comparison of pregnancy outcomes with the flexible GnRH antagonist protocol in an oocyte donation program | 31.7 | 0 | 2 |
| Oncologic oocyte cryopreservation for fertility preservation: national trends and comparison of cycle characteristics between women with and without cancer | 31.7 | 0 | 2 |
| Elective egg freezing and male support: a qualitative study of men’s hidden roles in women’s fertility preservation | 31.7 | 0 | 2 |
| Risk of ectopic pregnancy after different ovarian stimulation protocols in fresh single embryo transfer: analysis of 71,831 cycles from the Japanese ART registry | 31.7 | 0 | 2 |
| Oocyte retrieval rate through repeated identical controlled ovarian stimulation cycles in donors. | 31.7 | 0 | 2 |
| Does myotonic dystrophy affect ovarian reserve, response to controlled ovarian stimulation and ivf-preimplantation genetic diagnosis outcome in female patients? | 31.7 | 0 | 2 |
| Selective Discontinuation of Luteal Phase Support in Assisted Reproduction Cycles Using a Gonadotropin-Releasing Hormone Agonist and Human Menopausal Gonadotropins for Ovarian Stimulation | 31.7 | 0 | 2 |
| Association between the number of oocytes retrieved and cumulative live birth rate in IVF treatment: menopur in GnRH antagonist single embryo transfer - high responder (MEGASET-HR) trial outcomes | 31.7 | 0 | 2 |
| Recent Advances in Reproductive Endocrinology: Implications for Fertility Treatment in Gynecology | 31.7 | 0 | 2 |
| What are the benefits and harms of intrauterine administration of human chorionic gonadotropin (hCG) around the time of embryo transfer for subfertile women undergoing assisted reproduction? | 31.7 | 0 | 2 |
| Anti-mullerian hormone and antral follicle count in polycystic ovary syndrome and non-polycystic ovary syndrome women | 31.7 | 0 | 2 |
| Impacts of endometrioma type and two-different techniques of laparoscopic cystectomyon ovarian reserve by measuring anti-mullerian hormone concentration | 31.7 | 0 | 2 |
| Studying the Effect of Laparoscopic Ovarian Drilling on Ovarian Reserve via Measurement of Anti-Mullerian Hormone in Polycystic Ovarian Syndrome Patients | 31.7 | 0 | 2 |
| 106 Effect of Heat-Stress on Antral Follicle Count and Serum Concentration of Anti-Mullerian Hormone in Bos taurus Crossbred Beef Cows | 31.7 | 0 | 2 |
| Recombinant FSH dosing during controlled ovarian stimulation in IVF treatment | 31.7 | 0 | 2 |
| The relevance of antral follicle count (AFC) as a marker of ovarian reserve in normal and infertile women in a tertiary care centre in Central India | 31.7 | 0 | 2 |
| Impact of the Duration of Controlled Ovarian Stimulation on Assisted Reproduction Cycle Outcomes | 31.7 | 0 | 2 |
| Singletons birthweight after frozen-thawed embryo transfer is increased after endometrial preparation with artificial cycle compared to mild gonadotropin ovarian stimulation | 31.7 | 0 | 2 |
| Ovarian stimulation is a safe and effective fertility preservation (FP) option in the adolescent population | 31.7 | 0 | 2 |
| Egg freezing for fertility preservation and family planning: a survey of OB/GYN residents across united states | 31.7 | 0 | 2 |
| Random start versus conventional start controlled ovarian stimulation in women with cancer: comparing oocyte yield among fertility preservation cycles | 31.7 | 0 | 2 |
| Day 6 blastocysts have higher aneuploidy rates compared to day 5 blastocyts after standardized controlled ovarian stimulation protocol | 31.7 | 0 | 2 |
| impact of breast cancer prognostic factors on the response to controlled ovarian stimulation patients undergoing fertility preservation | 31.7 | 0 | 2 |
| Is ovarian reserve and reproductive outcome compromised in breast cancer patients? experience in 1000 women undergoing fertility preservation (FP) | 31.7 | 0 | 2 |
| Ovarian reserve tests are associated with the number of oocytes matured in vitro and with the primordial follicle density in a population of candidates for fertility preservation | 31.7 | 0 | 2 |
| Assisted reproduction technology: Comparison of anesthetic techniques for oocyte retrieval in a tertiary health facility in Ilorin, Nigeria | 31.7 | 0 | 2 |
| How does freeze-all strategy compare with conventional in vitro fertilization and fresh embryo transfer during assisted reproduction? | 31.7 | 0 | 2 |
| Intracytoplasmic Sperm Injection Outcome in Patient at Risk of Poor Responder Using Mild Ovarian Stimulation Protocol versus Short Gonadotropin Releasing Hormone Agonist Protocol | 31.7 | 0 | 2 |
| Antral Follicle Count and AMH Level for Ovarian Reserve Comparison | 31.7 | 0 | 2 |
| An artificial intelligence tool predicts blastocyst development from static images of fresh mature oocytes | 31.7 | 0 | 2 |
| Impact of Egg Storage Duration and Temperature on Egg Quality, Fertility, Hatchability and Chick Quality in Naked Neck Chickens | 31.7 | 0 | 2 |
| Antral Follicle Count versus Basal Follicle Stimulating Hormone as Predictors of Ovarian Response in Women Undergoing Superovulation with Long Protocol for Assisted Reproduction | 31.7 | 0 | 2 |
| Q135289054 | 31.7 | 0 | 2 |
| Q137191214 | 31.7 | 0 | 2 |
| Q137191215 | 31.7 | 0 | 2 |
| Q137191216 | 31.7 | 0 | 2 |
| Q137191222 | 31.7 | 0 | 2 |
| Cyprus Fertina IVF Clinic | 31.7 | 0 | 2 |
| double ovarian stimulation | 31.7 | 0 | 2 |
| The Story of the Weeping Camel | 25.8 | 1 | 0 |
| National Geographic | 25.8 | 1 | 0 |
| Sea Monsters: A Prehistoric Adventure | 25.8 | 1 | 0 |
| United States Centers for Disease Control and Prevention | 25.8 | 1 | 0 |
| Q636192 | 25.8 | 1 | 0 |
| Cystic Fibrosis Foundation | 25.8 | 1 | 0 |
| Johns Hopkins School of Medicine | 25.8 | 1 | 0 |
| NewYork–Presbyterian Hospital | 25.8 | 1 | 0 |
| Johns Hopkins Hospital | 25.8 | 1 | 0 |
| Mount Sinai Hospital | 25.8 | 1 | 0 |
| polymyalgia rheumatica | 25.8 | 1 | 0 |
| Morbidity and Mortality Weekly Report | 25.8 | 1 | 0 |
| Lou Ruvo Center for Brain Health | 25.8 | 1 | 0 |
| UCLA Ronald Reagan Medical Center | 25.8 | 1 | 0 |
| Mayo Clinic Hospital — Rochester | 25.8 | 1 | 0 |
| Brigham and Women's Hospital | 25.8 | 1 | 0 |
| National Center for Health Statistics | 25.8 | 1 | 0 |
| Aberdeen Maternity Hospital | 25.8 | 1 | 0 |
| Aberdeen Royal Infirmary | 25.8 | 1 | 0 |
| Advisory Committee on Immunization Practices | 25.8 | 1 | 0 |
| Johns Hopkins All Children's Hospital | 25.8 | 1 | 0 |
| Anne Schuchat | 25.8 | 1 | 0 |
| Arthur L. Jenkins | 25.8 | 1 | 0 |
| Baylor University Medical Center at Dallas | 25.8 | 1 | 0 |
| California Pacific Medical Center | 25.8 | 1 | 0 |
| Chalmers Hospital | 25.8 | 1 | 0 |
| Color labs | 25.8 | 1 | 0 |
| Cooper University Hospital | 25.8 | 1 | 0 |
| Corinne Goldsmith Dickinson Center for Multiple Sclerosis | 25.8 | 1 | 0 |
| Cosmos: A Spacetime Odyssey | 25.8 | 1 | 0 |
| Emerging Infectious Diseases | 25.8 | 1 | 0 |
| Deaconess Hospital | 25.8 | 1 | 0 |
| Dr Gray's Hospital | 25.8 | 1 | 0 |
| Epi Map | 25.8 | 1 | 0 |
| Epidemic Intelligence Service | 25.8 | 1 | 0 |
| Fire Fighter Fatality Investigation and Prevention Program | 25.8 | 1 | 0 |
| Fleming Cottage Hospital | 25.8 | 1 | 0 |
| Glen O'Dee Hospital | 25.8 | 1 | 0 |
| Health Hazard Evaluation | 25.8 | 1 | 0 |
| Systems Biology in Reproductive Medicine | 20.0 | 0 | 1 |
| Robert Edwards | 20.0 | 0 | 1 |
| circadian rhythm | 20.0 | 0 | 1 |
| embryo transfer | 20.0 | 0 | 1 |
| reproductive medicine | 20.0 | 0 | 1 |
| AMH | 20.0 | 0 | 1 |
| chronobiology | 20.0 | 0 | 1 |
| egg donation | 20.0 | 0 | 1 |
| Biological clock | 20.0 | 0 | 1 |
| embryo cryopreservation | 20.0 | 0 | 1 |
| Creighton Model FertilityCare System | 20.0 | 0 | 1 |
| biological clock | 20.0 | 0 | 1 |
| Center for Reproductive Medicine | 20.0 | 0 | 1 |
| Egg Banking | 20.0 | 0 | 1 |
| Endocrinology of reproduction | 20.0 | 0 | 1 |
| fertility preservation | 20.0 | 0 | 1 |
| Fertility testing | 20.0 | 0 | 1 |
| fertility tourism | 20.0 | 0 | 1 |